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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data upon
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College of
ardiology/American Heart Association (ACC/AHA) Task
orce on Practice Guidelines has created a new “focused
pdate” process to revise the existing guideline recommenda-
ions that are affected by evolving data or opinion. Before the
nitiation of this focused approach, periodic updates and
evisions of existing guidelines required up to 3 years to
omplete. Now, however, new evidence will be reviewed in an
ngoing fashion to more efficiently respond to important
cience and treatment trends that could have a major impact on
atient outcomes and quality of care. Evidence will be reviewed
t least twice a year, and updates will be initiated on an as
eeded basis as quickly as possible while maintaining the
igorous methodology that the ACC and AHA have devel-
ped during their more than 20 years of partnership.
These updated guideline recommendations reflect a con-
ensus of expert opinion following a thorough review
rimarily of late-breaking clinical trials identified through a
road-based vetting process as important to the relevant
atient population and of other new data deemed to have an
mpact on patient care (see Section 1.1 for details regarding
his focused update). It is important to note that this
ocused update is not intended to represent an update based
n a full literature review from the date of the previous
uideline publication. Specific criteria/considerations for
nclusion of new data include:
Publication in a peer-reviewed journal
Large, randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results that impact current safety and efficacy assumptions
Strengths/weakness of research methodology and findings
Likelihood of additional studies influencing current findings
Impact on current performance measure(s) and/or likeli-
hood of the need to develop new performance measure(s)
Requests and requirements for review and update from
the practice community, key stakeholders, regulatory
agencies, and other sources free of relationships with
industry or other potential bias
Number of previous trials showing consistent results
Need for consistency with other new guidelines or
guideline revisions
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PCI Focused Update January 15, 2008:172–209In analyzing the data and developing updated recommen-
ations and supporting text, the focused update writing
roup used evidence-based methodologies developed by the
CC/AHA Task Force on Practice Guidelines, which are
escribed elsewhere (1,2).
The schema for class of recommendation and level of
vidence is summarized in Table 1, which also illustrates how
he grading system provides estimates of the size of the
reatment effect and the certainty of the treatment effect. Note
hat a recommendation with Level of Evidence B or C does
ot imply that the recommendation is weak. Many important
linical questions addressed in guidelines do not lend them-
elves to clinical trials. Although randomized trials may not be
vailable, there may be a very clear clinical consensus that a
articular test or therapy is useful and effective. Both the class
f recommendation and level of evidence listed in the focused
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopu
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension ofpdates are based on consideration of the evidence reviewed in hrevious iterations of the guidelines as well as the focused
pdate. Of note, the implications of older studies that have
nformed recommendations but have not been repeated in
ontemporary settings are carefully considered.
The ACC/AHA practice guidelines address patient pop-
lations (and health care providers) residing in North
merica. As such, drugs that are not currently available in
orth America are discussed in the text without a specific
lass of recommendation. For studies performed in large
umbers of subjects outside of North America, each writing
ommittee reviews the potential impact of different practice
atterns and patient populations on the treatment effect and
n the relevance to the ACC/AHA target population to
etermine whether the findings should form the basis of a
pecific recommendation.
The ACC/AHA practice guidelines are intended to assist
vidence†
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow queries at the individual recommendation level.l of E
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iting reealth care providers in clinical decision making by describ-
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January 15, 2008:172–209 PCI Focused Updateng a range of generally acceptable approaches for the
iagnosis, management, and prevention of specific diseases
r conditions. The guidelines attempt to define practices
hat meet the needs of most patients in most circumstances.
he ultimate judgment regarding care of a particular patient
ust be made by the health care provider and patient in
ight of all the circumstances presented by that patient.
hus, there are circumstances in which deviations from
hese guidelines may be appropriate. Clinical decision mak-
ng should consider the quality and availability of expertise
n the area where care is provided. These guidelines may be
sed as the basis for regulatory or payer decisions, but the
ltimate goal is quality of care and serving the patient’s best
nterests.
Prescribed courses of treatment in accordance with these
ecommendations are only effective if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, health care providers should
ake every effort to engage the patient in active participa-
ion with prescribed treatment.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflict of interest arising from industry relationships
r personal interests of a writing committee member. All
riting committee members and peer reviewers were re-
uired to provide disclosure statements of all such relation-
hips pertaining to the trials and other evidence under
onsideration (see Appendixes 1 and 2). Final recommen-
ations were balloted to all writing committee members.
riting committee members with significant (greater than
10 000) relevant relationships with industry (RWI) were
equired to recuse themselves from voting on that recom-
endation. Writing committee members who did not
articipate are not listed as authors of this focused update.
With the exception of the recommendations presented in
his statement, the full guidelines remain current. Only the
ecommendations from the affected section(s) of the full
uidelines are included in this focused update. For easy
eference, all recommendations from any section of guide-
ines impacted by a change are presented with a notation as
o whether they remain current, are new, or have been
odified. When evidence impacts recommendations in
ore than 1 set of guidelines, those guidelines are updated
oncurrently.
The recommendations in this focused update will be
onsidered current until they are superseded by another
ocused update or the full-text guidelines are revised. This
ocused update is published in the January 15, 2008, issue of
he Journal of the American College of Cardiology and the
anuary 15, 2008, issue of Circulation and e-published in
atheterization and Cardiovascular Interventions as an up-
ate to the full-text guidelines and is also posted on the
CC (www.acc.org), AHA (www.americanheart.org), and
ociety for Angiography and Interventions (SCAI) (www.
cai.org) Web sites. Copies of the focused update are
vailable from all organizations. SSidney C. Smith, Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Evidence Review
elected late-breaking clinical trials presented at the 2005
nd 2006 annual scientific meetings of the ACC, AHA, and
uropean Society of Cardiology, as well as selected other
ata, were reviewed by the standing guideline writing
ommittee along with the parent Task Force and other
xperts to identify those trials and other key data that might
mpact guideline recommendations. On the basis of the
riteria/considerations noted above, recent trial data and
ther clinical information were considered important
nough to prompt a focused update of the ACC/AHA/
CAI 2005 Guideline Update for Percutaneous Coronary
ntervention (3–13).
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
rms of clinical trials are presented to permit calculation of
he absolute risk difference (ARD) and number needed to
reat (NNT) or harm (NNH); the relative treatment effects
re described either as odds ratio (OR), relative risk (RR), or
azard ratio (HR), depending on the format in the original
ublication.
Consult the full-text version or executive summary of the
CC/AHA/SCAI 2005 Guideline Update for Percutane-
us Coronary Intervention for policy on clinical areas not
overed by the focused update (13a). Individual recommen-
ations updated in this focused update will be incorporated
nto future revisions and/or updates of the full-text guide-
ines.
.2. Organization of Committee and
elationships With Industry
or this focused update, all members of the 2005 PCI
riting committee were invited to participate; those who
greed (referred to as the 2007 focused update writing
roup) were required to disclose all RWI relevant to the data
nder consideration (2). Focused update writing group
embers who had no significant relevant RWI wrote the
rst draft of the focused update; the draft was then reviewed
nd revised by the full writing group. Each recommendation
equired a confidential vote by the writing group members
efore external review of the document. Any writing com-
ittee member with a significant (greater than $10 000)
WI relevant to the recommendation was recused from
oting on that recommendation.
.3. Review and Approval
his document was reviewed by 2 outside reviewers nomi-
ated by each cosponsoring organization (ACC, AHA, and
CAI) and 24 individual content reviewers. All reviewer
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PCI Focused Update January 15, 2008:172–209WI information was collected and distributed to the
riting committee and is published in this document (see. Patients With Unstable Angina/Non–ST-Elevat
atients With Unstable Angina/Non–ST-Elevation Myo-
c
a
p
tThis document was approved for publication by the
overning bodies of the American College of Cardiologyppendix 2 for details). Foundation, the AHA, and SCAI.ion Myocardial Infarctionhis 2007 PCI Focused Update section regarding patients
ith unstable angina (UA)/non–ST-elevation myocardial
nfarction (NSTEMI) is based on recommendations from
he ACC/AHA 2007 Guidelines for the Management ofardial Infarction (14), which emphasize the importance of
ssessing risk of cardiovascular events as a guide to thera-
eutic decision making and the need for interventional
herapy (see Table 2).able 2. Updates to Section 5.3: Initial Conservative Versus In
2005 PCI Guideline Update Recommendation 2007 PCI F
C
n early invasive PCI strategy is indicated for patients with
UA/NSTEMI who have no serious comorbidity† and
coronary lesions amenable to PCI. Patients must have
any of the following high-risk features:
a. Recurrent ischemia despite intensive anti-ischemic
therapy. (Level of Evidence: A)
b. Elevated troponin level. (Level of Evidence: A)
c. New ST-segment depression. (Level of Evidence: A)
d. HF symptoms or new or worsening MR. (Level of
Evidence: A)
e. Depressed LV systolic function. (Level of Evidence: A)
f. Hemodynamic instability. (Level of Evidence: A)
g. Sustained ventricular tachycardia. (Level of Evidence: A)
h. PCI within 6 months. (Level of Evidence: A)
i. Prior CABG. (Level of Evidence: A)
j. High risk score (e.g., TIMI, GRACE). (Level of Evidence: A)
k. High risk findings from non-invasive testing. (Level of
Evidence: A)
1. An early invasi
with UA/NSTEM
and who have
who have char
Table 3 and Se
UA/NSTEMI Gu
2. Percutaneous
recommended
vessel CAD wit
anterior desce
viable myocard
noninvasive te
3. Percutaneous
recommended
multivessel co
anatomy, with
diabetes melli
4. An intravenous
UA/NSTEMI pa
Evidence: A) S
2007 ACC/AH
5. An early invasi
with intent to p
UA/NSTEMI pa
hemodynamic
comorbidities
(Level of Evideitial Invasive Strategies (Patients With UA/NSTEMI)
ocused Update Recommendation Comments
lass I
ve PCI strategy is indicated for patients
I who have no serious comorbidity†
coronary lesions amenable to PCI and
acteristics for invasive therapy (see
ction 3.3 of the ACC/AHA 2007
idelines) (14). (Level of Evidence: A)
Modified recommendation*
coronary intervention (or CABG) is
for UA/NSTEMI patients with 1- or 2-
h or without significant proximal left
nding CAD but with a large area of
ium and high-risk criteria on
sting. (Level of Evidence: B)
New recommendation*
coronary intervention (or CABG) is
for UA/NSTEMI patients with
ronary disease with suitable coronary
normal LV function, and without
tus. (Level of Evidence: A)
New recommendation*
platelet GP IIb/IIIa inhibitor is useful in
tients undergoing PCI. (Level of
ee Section 3.2.3 and Table 13 of the
A 2007 UA/NSTEMI Guidelines (14).
New recommendation*
ve strategy (i.e., diagnostic angiography
erform revascularization) is indicated in
tients who have refractory angina or
or electrical instability (without serious
or contraindications to such procedures).
nce: B)
New recommendation*
TI
I
U
I
P
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2005 PCI Guideline Update Recommendation 2007 PCI Focused Update Recommendation Comments
Class IIa
t is reasonable that PCI be performed in patients with UA/
NSTEMI and single-vessel or multivessel CAD who are
undergoing medical therapy with focal saphenous vein
graft lesions or multiple stenoses who are poor candidates
for reoperative surgery. (Level of Evidence: C)
1. Percutaneous coronary intervention is reasonable for
focal saphenous vein graft lesions or multiple stenoses
in UA/NSTEMI patients who are undergoing medical
therapy and who are poor candidates for reoperative
surgery. (Level of Evidence: C)
Modified recommendation*
n the absence of high-risk features associated with UA/
NSTEMI, it is reasonable to perform PCI in patients with
amenable lesions and no contraindication for PCI with
either an early invasive or early conservative strategy.
(Level of Evidence: B)
Deleted recommendation*
2. Percutaneous coronary intervention (or CABG) is
reasonable for UA/NSTEMI patients with 1- or 2-vessel
CAD with or without significant proximal left anterior
descending CAD but with a moderate area of viable
myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
New recommendation*
3. Percutaneous coronary intervention (or CABG) can be
beneficial compared with medical therapy for
UA/NSTEMI patients with 1-vessel disease with
significant proximal left anterior descending CAD.
(Level of Evidence: B)
New recommendation*
se of PCI is reasonable in patients with UA/NSTEMI with
significant left main CAD (greater than 50% diameter
stenosis) who are candidates for revascularization but
are not eligible for CABG. (Level of Evidence: B)
4. Use of PCI is reasonable in patients with UA/NSTEMI
with significant left main CAD (greater than 50%
diameter stenosis) who are candidates for
revascularization but are not eligible for CABG or who
require emergency intervention at angiography for
hemodynamic instability. (Level of Evidence: B)
2005 recommendation remains current
in 2007 PCI Update but receives
additional wording.
Class IIb
n the absence of high-risk features associated with UA/
NSTEMI, PCI may be considered in patients with single-
vessel or multivessel CAD who are undergoing medical
therapy and who have 1 or more lesions to be dilated
with a less than optimal likelihood of success. (Level of
Evidence: B)
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI may be considered in patients with
single-vessel or multivessel CAD who are undergoing
medical therapy and who have 1 or more lesions to be
dilated with a reduced likelihood of success. (Level of
Evidence: B)
Modified recommendation*
CI may be considered in patients with UA/NSTEMI who
are undergoing medical therapy who have 2- or 3-vessel
disease, significant proximal LAD CAD, and treated
diabetes or abnormal LV function. (Level of Evidence: B)
2. PCI may be considered in patients with UA/NSTEMI
who are undergoing medical therapy who have 2- or
3-vessel disease, significant proximal left anterior
descending CAD, and treated diabetes or abnormal LV
function, with anatomy suitable for catheter-based
therapy. (Level of Evidence: B)
2005 recommendation remains current
in 2007 PCI Update but receives
additional wording.
3. In initially stabilized patients, an initially conservative
(i.e., a selectively invasive) strategy may be considered
as a treatment strategy for UA/NSTEMI patients
(without serious comorbidities or contraindications to
such procedures†) who have an elevated risk for
clinical events (see Table 3) including those who are
troponin positive. (Level of Evidence: B). The decision
to implement an initial conservative (versus initial
invasive) strategy‡ in these patients may be made by
considering physician and patient preference. (Level of
Evidence: C)
New recommendation*
4. An invasive strategy may be reasonable in patients
with chronic renal insufficiency. (Level of Evidence: C)
New recommendation*
Class III
1. Percutaneous coronary intervention (or CABG) is not
recommended for patients with 1- or 2-vessel CAD
without significant proximal left anterior descending
CAD with no current symptoms or symptoms that are
unlikely to be due to myocardial ischemia and who
have no ischemia on noninvasive testing. (Level of
Evidence: C)
New recommendation*
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PCI Focused Update January 15, 2008:172–209Because of the importance of several new changes in the
CC/AHA 2007 UA/NSTEMI Guidelines, selected text
rom the guidelines is included in the following paragraphs
nd summarized in Table 2.
A number of risk-assessment tools have been developed
o assist in assessing risk of death and ischemic events in
atients with UA/NSTEMI, thereby providing a basis for
herapeutic decision making. It should be recognized that
he predictive ability of these commonly used risk assess-
able 3. Selection of Initial Treatment Strategy:
nvasive Versus Conservative Strategy
Preferred Strategy Patient Characteristics
nvasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High-risk score (e.g., TIMI, GRACE)
Reduced LV function (LVEF less than 40%)
onservative Low-risk score (e.g., TIMI, GRACE)
Patient or physician preference in absence of high-
risk features
eprinted from the ACC/AHA 2007 UA/NSTEMI Guidelines (14).
CABG indicates coronary artery bypass graft surgery; GRACE, Global Registry of Acute Coronary
vents; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; PCI,
able 2. Continued
2005 PCI Guideline Update Recommendation 2007 PCI F
n the absence of high-risk features associated with UA/
NSTEMI, PCI is not recommended for patients with UA/
NSTEMI who have single-vessel or multivessel CAD and
no trial of medical therapy, or who have 1 or more of
the following:
2. In the absence
UA/NSTEMI, P
UA/NSTEMI wh
and no trial of
of the followin
. Only a small area of myocardium at risk. (Level of
Evidence: C)
. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success.
(Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality.
(Level of Evidence: C)
. Insignificant disease (less than 50% coronary stenosis).
(Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG.
(Level of Evidence: B)
a. Only a smal
Evidence: C)
b. All lesions o
morphology
success. (Le
c. A high risk o
mortality. (L
d. Insignificant
stenosis). (L
e. Significant l
(Level of Ev
3. A PCI strategy
No. 1 for speci
occluded infar
NSTEMI is not
Based on the ACC/AHA 2007 UA/NSTEMI Guidelines (14). †For example, severe hepatic, p
Diagnostic angiography with intent to perform revascularization.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; GP, glycoprotein;
escending; LV, left ventricular; MR, mitral regurgitation; PCI, percutaneous coronary interventio
ngina/non–ST-elevation myocardial infarction.ercutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; TnI, troponin I;
nd TnT, troponin T. Tent scores for risk of nonfatal coronary heart disease
CHD) is only moderate.
The Thrombolysis in Myocardial Infarction (TIMI) risk
core (15) is a simple tool composed of 7 (1-point) risk
ndicators rated on presentation (Table 4). The composite
nd points (all-cause mortality, new or recurrent myocardial
nfarction [MI], or severe recurrent ischemia prompting
rgent revascularization within 14 days) increase as the
IMI risk score increases. The TIMI risk score has been
alidated internally within the TIMI IIB trial and 2 separate
ohorts of patients from the ESSENCE (Efficacy and
afety of Subcutaneous Enoxaparin in Unstable Angina and
ed Update Recommendation Comments
h-risk features associated with
ot recommended for patients with
e single-vessel or multivessel CAD
al therapy, or who have 1 or more
2005 recommendation remains current
in 2007 PCI Update
of myocardium at risk. (Level of
ulprit lesion to be dilated with
onveys a low likelihood of
Evidence: C)
edure-related morbidity or
f Evidence: C)
se (less than 50% coronary
f Evidence: C)
in CAD and candidacy for CABG.
: B)
ble patients (see Table 12 Class III
ommendations) with persistently
ted coronary arteries after STEMI/
ted. (Level of Evidence: B)
New recommendation*
ry, or renal failure, or active/inoperable cancer. Clinical judgment is required in such cases.
, Global Registry of Acute Coronary Events; HF, heart failure; IV, intravenous; LAD, left anterior
, saphenous vein graft; TIMI, Thrombolysis in Myocardial Infarction; and UA/NSTEMI, unstable
able 4. TIMI Risk Score for Unstable Angina/
on–ST-Elevation Myocardial Infarction
TIMI Risk Score
All-Cause Mortality, New or Recurrent MI,
or Severe Recurrent Ischemia Requiring
Urgent Revascularization Through
14 Days After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
he TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point
s given for each of the following variables: age 65 years or older; at least 3 risk factors for CAD;
rior coronary stenosis of 50% or more; ST-segment deviation on ECG presentation; at least 2
nginal events in prior 24 hours; use of aspirin in prior 7 days; and elevated serum cardiac
iomarkers. Prior coronary stenosis of 50% or more remained relatively insensitive to missing
nformation and remained a significant predictor of events. Reprinted with permission from
ntman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation
I: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-42
15). Copyright © 2000 American Medical Association.ocus
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GRACECAD indicates coronary artery disease; ECG, electrocardiogram; MI, myocardial infarction; and
IMI, Thrombolysis in Myocardial Infarction.
N
r
r
e
g
a
s
w
t
w
c
i
v
o
e
u
a
N
A
r
t
m
t
w
o
a
s
E
t
t
w
a
U
n
p
t
a
c
d
d
1
m
i
n
t
c
P
a
(
(
d
1
b
r
p
S
i
p
S
d
o
d
N
A
T
A
a
t
h
p
t
(
s
2
T
e
d
w
w
e
s
r
d
N
u
n
C
s
A
t
e
s
a
(
I
m
r
i
o
P
t
t
b
N
179JACC Vol. 51, No. 2, 2008 King III et al.
January 15, 2008:172–209 PCI Focused Updateon–Q-Wave Myocardial Infarction) trial (16). The model
emained a significant predictor of events and appeared
elatively insensitive to missing information, such as knowl-
dge of previously documented coronary stenosis of 50% or
reater. The model’s predictive ability remained intact, with
cutoff of 65 years of age. The TIMI risk score was recently
tudied in an unselected emergency department population
ith chest pain syndrome; its performance was similar to
hat in the acute coronary syndrome (ACS) population from
hich it was derived and validated (17). The TIMI risk
alculator is available at www.timi.org. The TIMI risk
ndex, a modification of the TIMI risk score that uses the
ariables age, systolic blood pressure, and heart rate, has not
nly been shown to predict short-term mortality in ST-
levation myocardial infarction (STEMI) but also has been
seful in prediction of 30-day and 1-year mortality rates
cross the spectrum of patients with ACS, including UA/
STEMI (18).
The PURSUIT (Platelet Glycoprotein IIb-IIIa in Unstable
ngina: Receptor Suppression Using Integrilin Therapy) trial
isk model (19), based on patients enrolled in the PURSUIT
rial, is another useful tool to guide the clinical decision-
aking process when the patient is admitted to the hospital. In
he PURSUIT risk model, critical clinical features associated
ith an increased 30-day incidence of death and the composite
f death or myocardial (re)infarction were (in order of strength)
ge, heart rate, systolic blood pressure, ST-segment depression,
igns of heart failure (HF), and cardiac enzymes (19).
The GRACE (Global Registry of Acute Coronary
vents) study risk model, which predicts in-hospital mor-
ality (and death or MI), can be useful to clinicians to guide
reatment type and intensity (20,21). The GRACE risk tool
as developed on the basis of 11 389 patients in GRACE
nd validated in subsequent GRACE and GUSTO (Global
tilization of Streptokinase and TPA for Occluded Coro-
ary Arteries) IIb cohorts and predicts in-hospital death in
atients with STEMI, NSTEMI, or UA (C statis-
ic0.83). The 8 variables used in the GRACE risk model
re older age (OR 1.7 per 10 years), Killip class (OR 2.0 per
lass), systolic blood pressure (OR 1.4 per 20 mm Hg
ecrease), ST-segment deviation (OR 2.4), cardiac arrest
uring presentation (OR 4.3), serum creatinine level (OR
.2 per 1 mg per dL increase), positive initial cardiac
arkers (OR 1.6), and heart rate (OR 1.3 per 30-bpm
ncrease). The sum of scores is applied to a reference
onogram to determine the corresponding all-cause mor-
ality from hospital discharge to 6 months. The GRACE
linical application tool can be downloaded to a handheld
DA (personal digital assistant) to be used at the bedside
nd is available at www.outcomes-umassmed.org/grace
Figure 1) (21). An analysis comparing the 3 risk scores
TIMI, GRACE, and PURSUIT) concluded that all 3
emonstrated good predictive accuracy for death and MI at
year, thus identifying patients who might be likely to
enefit from aggressive therapy, including early myocardial
evascularization (22). fiThe electrocardiogram (ECG) provides unique and im-
ortant diagnostic and prognostic information (see also
ection 2.1 below). Accordingly, ECG changes have been
ncorporated into quantitative decision aids for the triage of
atients who present with chest discomfort (23). Although
T elevation carries the highest early risk of death, ST
epression on the presenting ECG portends the highest risk
f death at 6 months, with the degree of ST-segment
epression showing a strong relationship to outcome (24).
The recommendations in the ACC/AHA 2007 UA/
STEMI Guidelines (14) recognize recent data from the
CUITY (Acute Catheterization and Urgent Intervention
riage strategY) trial, which showed that in patients with
CS who were undergoing invasive treatment, bivalirudin
lone was associated with rates of ischemia similar to those
reated with glycoprotein (GP) IIb/IIIa inhibitors plus
eparin and significantly less bleeding (25).
The ACC/AHA 2007 UA/NSTEMI Guidelines cite a
rogressively greater benefit from newer, more aggressive
herapies such as low-molecular-weight heparin (LMWH)
16,26), platelet GP IIb/IIIa inhibition (27), and an invasive
trategy (28) with increasing risk score.
.1. Electrocardiogram
he ECG lies at the center of the decision pathway for the
valuation and management of patients with acute ischemic
iscomfort (Table 5). The diagnosis of MI is confirmed
ith serial cardiac biomarkers in more than 90% of patients
ho present with ST-segment elevation greater than or
qual to 1 mm (0.1 mV) in at least 2 contiguous leads, and
uch patients should be considered candidates for acute
eperfusion therapy. Patients who present with ST-segment
epression are initially considered to have either UA or
STEMI; the distinction between the 2 diagnoses is
ltimately based on the detection of markers of myocardial
ecrosis in the blood (29–31).
Up to 25% of patients with NSTEMI and elevated
K-MB go on to develop Q-wave MI during their hospital
tay, whereas the remaining 75% have non–Q-wave MI.
cute fibrinolytic therapy is contraindicated for ACS pa-
ients without ST-segment elevation, except for those with
lectrocardiographic true posterior MI manifested as ST-
egment depression in 2 contiguous anterior precordial leads
nd/or isolated ST-segment elevation in posterior chest lead
32–34). Inverted T waves may also indicate UA/NSTEMI.
n patients suspected of having ACS on clinical grounds,
arked (greater than or equal to 2 mm [0.2 mV]) symmet-
ical precordial T-wave inversion strongly suggests acute
schemia, particularly that associated with a critical stenosis
f the left anterior descending coronary artery (LAD) (35).
atients with this ECG finding often exhibit hypokinesis of
he anterior wall and are at high risk if given medical
reatment alone (36). Revascularization will often reverse
oth the T-wave inversion and wall-motion disorder (37).
onspecific ST-segment and T-wave changes, usually de-
ned as ST-segment deviation less than 0.5 mm (0.05 mV)
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PCI Focused Update January 15, 2008:172–209r T-wave inversion less than or equal to 2 mm (0.2 mV),
re less diagnostically helpful than the foregoing findings.
stablished Q waves greater than or equal to 0.04 second
re also less helpful in the diagnosis of UA, although by
uggesting prior MI, they do indicate a high likelihood of
ignificant coronary artery disease (CAD). Isolated Q waves
n lead III may be a normal finding, especially in the absence
f repolarization abnormalities in any of the inferior leads.
completely normal ECG in a patient with chest pain does
ot exclude the possibility of ACS, because 1% to 6% of
uch patients eventually are proven to have had an MI (by
efinition, NSTEMI), and at least 4% will be found to have
A (38–40).
In addition to the presence or absence of ST-segment
eviation or T-wave inversion patterns noted earlier, there is
vidence that the magnitude of the ECG abnormality
igure 1. GRACE Prediction Score Card and Nomogram for All-Cau
eprinted with permission from (20). Copyright © 2004 American Medical Associatiorovides important prognostic information. Thus, Lloyd- Gones et al. (41) reported that the diagnosis of acute
on–Q-wave MI was 3 to 4 times more likely in patients
ith ischemic discomfort who had at least 3 ECG leads that
howed ST-segment depression and maximal ST depression
f greater than or equal to 0.2 mV. Investigators from the
IMI III Registry (42) reported that the 1-year incidence of
eath or new MI in patients with at least 0.5 mm (0.05 mV)
f ST-segment deviation was 16.3% compared with 6.8%
or patients with isolated T-wave changes and 8.2% for
atients with no ECG changes.
Cardiogenic shock can occur in the setting of both
TEMI and NSTEMI, and there is high mortality and
orbidity in each. The SHOCK (SHould we emergently
evascularize Occluded Coronaries for cardiogenic shocK)
tudy (43) found that approximately 20% of all cardiogenic
hock complicating MI was associated with NSTEMI. The
ortality From Discharge to 6 Monthsse MUSTO-II (44) and PURSUIT (45) trials found that
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January 15, 2008:172–209 PCI Focused Updateardiogenic shock occurs in up to 5% of patients with
STEMI and that mortality rates are greater than 60%.
hus, hypotension and evidence of organ hypoperfusion can
ccur and constitute a medical emergency in NSTEMI.
.1.1. Comparison of Early Invasive and Initial Conser-
ative Strategies for UA/NSTEMI
rior meta-analyses concluded that routine invasive therapy
the “invasive” or “early” strategy triages patients to undergo
n invasive diagnostic evaluation without first getting a
oninvasive stress test or without failing medical treatment
i.e., an initial conservative diagnostic strategy or sometimes
ow known as the “selective invasive strategy”] (14)) is
etter than an initial conservative or selectively invasive
pproach (the “initial conservative strategy” [also referred to
s “selective invasive management”] calls for proceeding
ith an invasive evaluation only for those patients who fail
edical therapy [refractory angina or angina at rest or with
inimal activity despite rigorous medical therapy] or in
hom objective evidence of ischemia [dynamic ECG
hanges, high-risk stress test] is identified (14)). Mehta et
l. (47) concluded that the routine invasive strategy resulted
n an 18% relative reduction in death or MI, including a
ignificant reduction in MI alone. The routine invasive arm
as associated with higher in-hospital mortality (1.8%
ersus 1.1%), but this disadvantage was more than compen-
ated for by a significant reduction in mortality between
ischarge and the end of follow-up (3.8% versus 4.9%). In
hose analyses, the invasive strategy was associated with less
ngina and fewer rehospitalizations than the conservative
athway. Patients undergoing routine invasive treatment
lso had improved quality of life.
In contrast to these findings, other studies, most recently
CTUS (Invasive versus Conservative Treatment in Unsta-
le coronary Syndromes), have favorably highlighted a
trategy of selective invasive therapy (48). In ICTUS, 1200
able 5. Likelihood That Signs and Symptoms Represent an Ac
Feature
High Likelihood
Any of the following:
istory Chest or left arm pain or discomfort
as chief symptom reproducing
prior documented angina
Known history of CAD, including MI
C
A
M
D
xamination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema,
or rales
E
CG New, or presumably new, transient
ST-segment deviation (1 mm or
greater) or T-wave inversion in
multiple precordial leads
F
S
ardiac markers Elevated cardiac TnI, TnT, or CK-MB N
odified from (46). In the public domain.
CAD indicates coronary artery disease; CK-MB, MB fraction of creatine kinase; ECG, electrocaigh-risk ACS patients without ST-segment elevation were mandomized to receive routine invasive versus selective
nvasive management and followed up for 1 year with
espect to the combined incidence of death, MI, and
schemic rehospitalization. All patients were treated with
ptimal medical therapy that included aspirin, clopidogrel,
MWH, and lipid-lowering therapy; abciximab was given
o those undergoing revascularization. At the end of 1 year,
here was no significant difference in the composite end
oint between groups. This study suggests that a selective
nvasive strategy could be reasonable for ACS patients. A
ossible explanation for the lack of benefit of the invasive
pproach in this trial (and other trials) (49) could be related
o the relatively high rate of revascularization actually
erformed in patients treated in the selective invasive arm
47%), thereby reducing observed differences between treat-
ent strategies (22), and to the lower event rate (lower-risk
opulation) than in other studies. Results were unchanged
uring longer-term follow-up (50,51). Nevertheless, IC-
US required troponin positivity for entry. Thus, troponin
lone might no longer be an adequate criterion for strategy
election, especially with increasingly sensitive troponin
ssays. The degree of troponin elevation and other high-risk
linical factors taken together should be considered in
electing a treatment strategy. The ICTUS trial was rela-
ively underpowered for hard end points, and it used a
ontroversial definition for post procedural MI (i.e., even
inimal asymptomatic CK-MB elevation) (48,50,51).
Additionally, 1-year follow-up may be inadequate to fully
ealize the long-term impact and benefit of the routine
nvasive strategy. In the RITA-3 trial (Third Randomized
ntervention Trial of Angina), 5-year but not 1-year event
ates favored the early invasive arm (see Figure 2 and text
elow) (52). In ICTUS, however, results were maintained
uring a 3-year follow-up (53).
Thus, the 2007 UA/NSTEMI Guidelines (14) recom-
Coronary Syndrome Secondary to CAD
ntermediate Likelihood
sence of high-likelihood
features and presence
of any of the following:
Low Likelihood
Absence of high- or
intermediate-likelihood features
but may have the following:
or left arm pain or discomfort
hief symptom
eater than 70 years
ex
es mellitus
Probable ischemic symptoms in
absence of any intermediate-
likelihood characteristics
Recent cocaine use
rdiac vascular disease Chest discomfort reproduced by
palpation
waves
ression 0.5 to 1 mm or
ve inversion greater than
m
T-wave flattening or inversion less
than 1 mm in leads with
dominant R waves
Normal ECG
l Normal
m; MI, myocardial infarction; MR, mitral regurgitation; TnI, troponin I; and TnT, troponin T.ute
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PCI Focused Update January 15, 2008:172–209nitial conservative (selective invasive) strategy may be con-
idered as an alternative treatment option. The writing
ommittee also believes that additional comparative trials of
he selective invasive with the routine initial invasive strat-
gies are indicated, using aggressive contemporary medical
herapies in both arms, including routine dual antiplatelet
herapy (DAT) in medically treated patients as well as
ggressive lipid lowering and other updated secondary
revention measures.
Nevertheless, a meta-analysis of contemporary random-
zed trials in NSTEMI, including ICTUS, currently sup-
ort long-term mortality and morbidity benefits of an early
nvasive compared with an initial conservative strategy (54).
onfatal MI at 2 years (7.6% vs. 9.1%, respectively; RR 0.83
95% CI 0.72 to 0.96]; p 0.012) and hospitalization (at 13
onths; RR  0.69 [95% CI 0.65 to 0.74]; p less than
.0001) also were reduced by an early invasive strategy
Figure 3). A separate review of contemporary randomized
rials in the stent era using the Cochrane Database arrived at
imilar conclusions (55). Details of selected contemporary
rials of invasive versus conservative strategies may be found
igure 2. Cumulative Risk of Death or Myocardial Infarction
n RITA-3
op: Cumulative risk of death or myocardial infarction in the RITA-3 trial of patients
ith non-ST acute coronary syndrome. Bottom: Cumulative risk of death in the
ITA-3 trial of patients with non-ST acute coronary syndromes. Reprinted with
ermission from (52).n the ACC/AHA 2007 UA/NSTEMI Guidelines (14). 6Thus, the FRISC-II (Fragmin and Fast Revascularisation
uring InStability in Coronary artery disease) (56) and
ACTICS (Treat Angina with Aggrastat and Determine
ost of Therapy with an Invasive or Conservative Strategy)-
IMI 18 (28) trials showed a benefit in patients assigned to
nvasive strategy. In contrast to earlier trials, a large majority
f patients undergoing percutaneous coronary intervention
PCI) in these 2 trials received coronary stenting as opposed
o balloon angioplasty alone. Also, there was a differential
ate of thienopyridine use between the 2 arms; only stented
atients were treated. In FRISC-II, the invasive strategy
nvolved treatment with LMWH, aspirin, nitrates, and beta
lockers for an average of 6 days in the hospital before
oronary angiography, an approach that would be difficult to
dopt in US hospitals. In TACTICS-TIMI 18, treatment
ncluded the GP IIb/IIIa antagonist tirofiban, which was
dministered for an average of 22 hours before coronary
ngiography. The routine use of the GP IIb/IIIa inhibitor
n this trial may have eliminated the excess risk of early
within 7 days) MI in the invasive arm, a risk that was
bserved in FRISC-II and other trials in which there was no
outine “upstream” use of a GP IIb/IIIa blocker. Therefore,
n invasive strategy is associated with a better outcome in
A/NSTEMI patients at high risk as defined in Table 3
nd as demonstrated in TACTICS-TIMI 18 when a GP
Ib/IIIa inhibitor is used (28). Although the benefit of
ntravenous GP IIb/IIIa inhibitors is established for UA/
STEMI patients undergoing PCI, the optimal time to
tart these drugs before the procedure has not been estab-
ished. In the PURSUIT trial (45), in patients with UA/
STEMI who were admitted to community hospitals, the
dministration of eptifibatide was associated with a reduced
eed for transfer to tertiary referral centers and improved
utcomes (57).
The RITA-3 trial (52) compared early and conservative
herapy in 1810 moderate-risk patients with ACS. Patients
ith positive cardiac biomarkers (CK-MB greater than 2
imes the upper limit of normal at randomization) were
xcluded from randomization, as were those with new Q
aves, MI within 1 month, PCI within 1 year, and any prior
oronary artery bypass graft (CABG). The combined end
oint of death, nonfatal MI, and refractory angina was
educed from 14.5% to 9.6% by early invasive treatment.
he benefit was driven primarily by a reduction in refractory
ngina. There was a late divergence of the curves, with
educed 5-year death and MI in the early invasive arm
Figure 2).
In the VINO trial (Value of first day angiography/
ngioplasty In evolving Non-ST segment elevation myocar-
ial infarction: Open multicenter randomized trial) (58),
31 patients with NSTEMI were randomized to cardiac
atheterization on the day of admission versus conservative
herapy. Despite the fact that 40% of the conservatively
reated patients crossed over to revascularization by the
-month follow-up, there was a significant reduction in
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January 15, 2008:172–209 PCI Focused Updateigure 3. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI
: Relative risk of all-cause mortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent nonfatal myo-
ardial infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative risk of recurrent unstable angina resulting in
ehospitalization for early invasive therapy compared with conservative therapy at a mean follow-up of 13 months (54). CI indicates confidence interval; FRISC-II, FRagmin and
ast Revascularization during InStability in Coronary artery disease; ICTUS, Invasive versus Conservative Treatment in Unstable coronary Syndromes; ISAR-COOL, Intracoro-
ary Stenting with Antithrombotic Regimen COOLing-off; RITA-3, Third Randomized Intervention Trial of Angina; RR, relative risk; TIMI-18, Thrombolysis In Myocardial Infarction-
8; TRUCS, Treatment of Refractory Unstable angina in geographically isolated areas without Cardiac Surgery; UA/NSTEMI, unstable angina/non–ST-elevation myocardialnfarction; and VINO, Value of first day angiography/angioplasty In evolving Non-ST segment elevation myocardial infarction: Open multicenter randomized trial. Modified with
ermission from (54).
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PCI Focused Update January 15, 2008:172–209eath or reinfarction for patients assigned to early angiog-
aphy and revascularization (6% versus 22%).
The ISAR-COOL (Intracoronary Stenting with Anti-
hrombotic Regimen Cooling-off) trial (59) randomized
10 intermediate- to high-risk patients to very early angiog-
aphy and revascularization versus a delayed invasive strat-
gy. All patients were treated with intensive medical therapy
hat included aspirin, heparin, clopidogrel (600-mg loading
ose), and the intravenous GP IIb/IIIa receptor inhibitor
irofiban. In the very early arm, patients underwent cardiac
atheterization at a mean time of 2.4 hours versus 86 hours
n the delayed invasive arm. The very early invasive strategy
as associated with significantly better outcome at 30 days,
s measured by reduction in death and large MI (5.9%
ersus 11.6%). More importantly, the benefit seen was
ttributable to a reduction in events before cardiac cathe-
erization, which raises the possibility that there is a hazard
ssociated with a “cooling-down” period.
.1.2. Selection for Coronary Angiography
n contrast to the noninvasive tests, coronary angiography
rovides detailed structural information to allow assessment
able 7. Noninvasive Test Results That Predict High Risk for
dverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
xercise EF 0.50 or less Rest EF 0.35 or less
est EF 0.35 or less Wall-motion score index greater than 1
all in EF 0.10 or greater
able 6. Noninvasive Risk Stratification
igh risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score –11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake (thalliu
Stress-induced moderate perfusion defect with LV dilation or increased lung u
Echocardiographic wall-motion abnormality (involving more than 2 segments)
heart rate (less than 120 bpm)
Stress echocardiographic evidence of extensive ischemia
ntermediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF 0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased lun
Limited stress echocardiographic ischemia with a wall-motion abnormality on
ow risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited resting
Although published data are limited, patients with these findings will probably not be at low ris
.35). Reprinted from (60).
LV indicates left ventricular, and LVEF, left ventricular ejection fraction.odified from (61,62).
EF indicates ejection fraction. Mf prognosis and provide direction for appropriate manage-
ent. When combined with left ventricular (LV) angiog-
aphy, it also allows an assessment of global and regional LV
unction. Indications for coronary angiography are interwo-
en with indications for possible therapeutic plans, such as
CI or CABG.
Coronary angiography is usually indicated in patients
ith UA/NSTEMI who either have recurrent symptoms or
schemia despite adequate medical therapy or are at high
isk as categorized by clinical findings (HF, serious ventric-
lar arrhythmias) or noninvasive test findings (significant
V dysfunction: ejection fraction less than 0.35, large
nterior or multiple perfusion defects) (Tables 6, 7, and 8).
atients with UA/NSTEMI who have had previous PCI or
ABG also should generally be considered for early coro-
ary angiography unless prior coronary angiography data
ndicate that further revascularization is not likely to be
ossible. The placement of an intra-aortic balloon pump
IABP) may allow coronary angiography and revasculariza-
ion in those with hemodynamic instability. Patients with
uspected Prinzmetal’s variant angina also are candidates for
oronary angiography.
able 8. Noninvasive Test Results That Predict High Risk for
dverse Outcome on Stress Radionuclide Myocardial
erfusion Imaging
bnormal myocardial tracer distribution in more than 1 coronary artery region
at rest or with stress or a large anterior defect that reperfuses
bnormal myocardial distribution with increased lung uptake
ardiac enlargement
)
(thallium-201)
oping with low dose of dobutamine (10 mg/kg per min or less) or at a low
ke (thallium-201)
igher doses of dobutamine involving less than or equal to 2 segments
otion abnormalities during stress*
presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF less thanm-201
ptake
devel
g inta
ly at h
wall-m
k in theodified from (61).
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January 15, 2008:172–209 PCI Focused UpdateIn all cases, the general indications for coronary angiog-
aphy and revascularization are tempered by individual
atient characteristics and preferences. Patient and physi-
ian judgments regarding risks and benefits are particularly
mportant for patients who might not be candidates for
oronary revascularization, such as very frail older adults and
hose with serious comorbid conditions (i.e., severe hepatic,CI in patients with CKD is associated with a higher rate
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MI, un.1.3. Chronic Kidney Disease
he following recommendations have been added to the
CI Focused Update in accordance with new recommen-
ations appearing in the 2007 UA/NSTEMI Guidelines
14) (Table 9). Supporting text from that guidelines state-
ent is presented in the following paragraphs.ulmonary, or renal failure or active or inoperable cancer).Chronic kidney disease (CKD) is not only a coronary risk
quivalent for ascertainment of coronary risk but also a risk
actor for the development and progression of cardiovascular
isease (CVD) (63). CKD constitutes a risk factor for
dverse outcomes after MI (64), including NSTEMI and
ther coronary patient subsets. In the highly validated
RACE risk score, serum creatinine is 1 of 8 independent
redictors of death (20,65). In 1 recent study, even early
KD constituted a significant risk factor for cardiovascular
vents and death (64,66). CKD also predicts an increase in
ecurrent cardiovascular events (67). Cardiovascular death is
0 to 30 times higher in dialysis patients than in the general
opulation. The underrepresentation of patients with renal
isease in randomized controlled trials of CVD is a concern
68). Current opinion and most of the limited evidence
vailable suggest that when appropriately monitored, car-
iovascular medications and interventional strategies can be
pplied safely in those with renal impairment and provide
herapeutic benefit (64). However, not all recent evidence is
onsistent with this premise: atorvastatin did not signifi-
antly reduce the primary end point of cardiovascular death,
onfatal MI, or stroke in a prospective randomized trial of
atients with diabetes and end-stage CKD who were
ndergoing hemodialysis (69). The preference for primary
CI has also been questioned (70).
Particularly in the setting of ACS, bleeding complications
re higher in this patient subgroup because of platelet
ysfunction and dosing errors; benefits of fibrinolytic ther-
py, antiplatelet agents, and anticoagulants can be negated
r outweighed by bleeding complications; and renin-
ngiotensin-aldosterone inhibitors can impose a greater risk
ecause of the complications of hyperkalemia and worsen-
ng renal function in the patient with CKD. Angiography
arries an increased risk of contrast-induced nephropathy;
he usual benefits of PCI can be lessened or abolished; and
2005 PCI Guideline Update Recommendation 2007 PC
C
1. Creatinine cl
patients, and
be adjusted
2. In chronic ki
angiography
and are pref
Based on the ACC/AHA 2007 UA/NSTEMI Guidelines (14).
CKD indicates chronic kidney disease; PCI, percutaneous coronary intervention; and UA/NSTEf early and late complications of bleeding, restenosis, and
eath (68). Thus, identification of CKD is important in that
t represents an ACS subgroup with a far more adverse
rognosis but for whom interventions have less certain
enefit.
Coronary arteriography is a frequent component of the
are of ACS patients. As such, contrast-induced nephrop-
thy can constitute a serious complication of diagnostic and
nterventional procedures. In patients with CKD or CKD
nd diabetes, isosmolar contrast material lessens the rise in
reatinine and is associated with lower rates of contrast-
nduced nephropathy than low-osmolar contrast media.
his has been documented in a randomized clinical trial
RECOVER [Renal Toxicity Evaluation and Comparison
etween Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in
atients With Renal Insufficiency Undergoing Coronary
ngiography]) comparing iodixanol with ioxaglate (71) and
n a meta-analysis of 2727 patients from 16 randomized
linical trials (72).
Identification of patients with CKD as recommended in
he AHA Science Advisory on Detection of CKD in
atients with or at increased risk of CVD should guide the
se of isosmolar contrast agents (63). The advisory, which
as developed in collaboration with the National Kidney
oundation, recommends that all patients with CVD be
creened for evidence of kidney disease by estimating
lomerular filtration rate, testing for microalbuminuria, and
easuring the albumin-to-creatinine ratio. A glomerular
ltration rate of less than 60 ml per min per 1.73 square
eters of body surface should be regarded as abnormal.
urthermore, the albumin-to-creatinine ratio should be
sed to screen for the presence of kidney damage in adult
atients with CVD, with values greater than 30 mg of
lbumin per 1 g of creatinine considered abnormal.
A diagnosis of renal dysfunction is critical to proper
used Update Recommendation Comments
ce should be estimated in UA/NSTEMI
oses of renally cleared drugs should
priately. (Level of Evidence: B)
New recommendation*
isease patients undergoing
olar contrast agents are indicated
(Level of Evidence: A)
New recommendation*
stable angina/non–ST-elevation myocardial infarction.able 9. Indications for Chronic Kidney Disease
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PCI Focused Update January 15, 2008:172–209rugs used in patients with UA/NSTEMI are renally
leared; their doses should be adjusted for estimated creat-
nine clearance [see also Section 3 of the 2007 UA/
STEMI Guidelines (14)]. In a large community-based
egistry study, 42% of patients with UA/NSTEMI received
xcessive initial dosing of at least 1 antiplatelet or anti-
hrombin agent (unfractionated heparin [UFH], LMWH,
r GP IIb/IIIa inhibitor) (73). Renal insufficiency was an
ndependent predictor of excessive dosing. Dosing errors
redicted an increased risk of major bleeding. Clinical
tudies and labeling that defines adjustments for several of. Facilitated PCI
nfarct size or improving outcomes. The largest of these was
t
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h
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t
r
ion myoula for estimating creatinine clearance, which is not
dentical to the Modification of Diet and Renal Disease
MDRD) formula. Use of the Cockcroft-Gault formula to
enerate dose adjustments is recommended. The impact of
enal dysfunction on biomarkers of necrosis (i.e., troponin)
s discussed in Section 2.2.8.2.1 of the 2007 UA/NSTEMI
uidelines (14).
To increase the meager evidence base and to optimize
are for this growing high-risk population, the recognition
f CKD patients with or at risk of CVD and the inclusion
nd reporting of renal disease in large CVD trials must behese drugs have been based on the Cockcroft-Gault for- increased in the future.acilitated PCI refers to a strategy of planned immediate
CI after administration of an initial pharmacological
egimen intended to improve coronary patency before the
rocedure. These regimens have included high-dose hepa-
in, platelet GP IIb/IIIa inhibitors, full-dose or reduced-
ose fibrinolytic therapy, and the combination of a GP
Ib/IIIa inhibitor with a reduced-dose fibrinolytic agent
e.g., fibrinolytic dose typically reduced 50%). Facilitated
CI should be differentiated from primary PCI without
brinolytic therapy, from primary PCI with a GP IIb/IIIa
nhibitor started at the time of PCI, from early or delayed
CI after successful fibrinolytic therapy, and from rescue
CI after unsuccessful fibrinolytic therapy. Potential advan-
ages of facilitated PCI include earlier time to reperfusion,
maller infarct size, improved patient stability, lower infarct
rtery thrombus burden, greater procedural success rates,
igher TIMI flow rates, and improved survival rates. Po-
ential risks include increased bleeding complications, espe-
ially in older patients; potential limitations include added
ost.
Despite the potential advantages, clinical trials of facili-
ated PCI have not demonstrated any benefit in reducing
able 10. Updates to Section 5.4.3: PCI for STEMI in Conjunct
2005 PCI Guideline Update Recommendation 2007 PCI Fo
Cl
acilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not
immediately available and bleeding risk is low.
(Level of Evidence: B)
1. Facilitated P
dose fibrinol
a reperfusion
are present:
a. Patients a
b. PCI is not
minutes, a
c. Bleeding r
poorly con
weight). (L
C
1. A planned re
fibrinolytic th
may be harm
OE indicates level of evidence; PCI, percutaneous coronary intervention; and STEMI, ST-elevathe ASSENT-4 (Assessment of the Safety and Efficacy of a
ew Treatment Strategy with Percutaneous Coronary In-
ervention) PCI trial (5), in which 1667 patients were
andomized to full-dose tenecteplase and PCI versus pri-
ary PCI. The trial was terminated prematurely because of
higher in-hospital mortality rate in the facilitated PCI
roup (6% vs. 3%, p  0.01). The primary end point, a
omposite of death, shock, and congestive heart failure
ithin 90 days, was significantly higher with facilitated PCI
han with primary PCI (18.6% vs. 13.4%; p  0.0045), and
here was a trend toward higher 90-day mortality (6.7% vs.
.9%; p  0.14). Defenders of the facilitated PCI strategy
oint out that the absence of an infusion of heparin after
olus administration and of a loading dose of clopidogrel,
lus prohibition of GP IIb/IIIa inhibitors except in bail-out
ituations, made adjunctive antithrombotic therapy subop-
imal for the facilitated PCI group. Moreover, the median
reatment delay between tenecteplase and PCI was only 104
inutes, and mortality rates with facilitated PCI were
igher in PCI centers. Whether earlier (pre-hospital) ad-
inistration of fibrinolytic therapy, better antithrombotic
herapy, longer delays to PCI, or selective use of PCI as a
ith Concomitant Fibrinolytic Therapy
Update Recommendation Comments
b
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January 15, 2008:172–209 PCI Focused Updateeneficial is unclear and requires further study. On the basis
f these data, however, facilitated PCI offered no clinical
enefit.
Keeley and coworkers performed a quantitative review of
7 trials that compared facilitated PCI and primary PCI
74) (Figure 4). Included were 9 trials with GP IIb/IIIa
nhibitors alone (n 1148), 6 trials with fibrinolytic therapy
including ASSENT-4 PCI) (n  2953), and 2 trials with
fibrinolytic agent plus a GP IIb/IIIa inhibitor (n  399).
acilitated PCI with fibrinolytic therapy had significantly
igher rates of mortality, nonfatal reinfarction, urgent target
essel revascularization, total and hemorrhagic stroke, and
ajor bleeding compared with primary PCI. There were no
ifferences in efficacy or safety when facilitated PCI with a
P IIb/IIIa inhibitor was compared with primary PCI.
A planned reperfusion strategy using full-dose fibrinolytic
herapy followed by immediate PCI may be harmful (Table
0). Nevertheless, selective use of the facilitated strategy
ith regimens other than full-dose fibrinolytic therapy in
igh-risk subgroups of patients (large MI or hemodynamic
r electrical instability) with low bleeding risk who present
o hospitals without PCI capability might be performed
hen transfer delays for primary PCI are anticipated.
lthough the quantitative analysis showed no advantage for
retreatment with a GP IIb/IIIa inhibitor, neither did it
ocument any major disadvantage. The use of GP IIb/IIIa
nhibitors, particularly abciximab, during primary PCI is
ell established. Further trials of reduced-dose fibrinolytic
herapy, with or without GP IIb/IIIa inhibitors, are in
rogress and may yield different efficacy and/or safety
esults. For further clarification, please see Section
.3.1.6.2.1 of the 2004 ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial
igure 4. Short-Term Death in Patients Treated With Facilitated O
rials were classified by facilitated regimen. Diamonds and squares indicate odds ranfarction (75). iPharmacological reperfusion with full-dose fibrinolysis is
ot uniformly successful in restoring antegrade flow in the
nfarct artery. In such situations, a strategy of prompt
oronary angiography with intent to perform PCI is fre-
uently contemplated. In certain patients, such as those
ith cardiogenic shock (especially in those less than 75 years
f age), severe congestive heart failure/pulmonary edema, or
emodynamically compromising ventricular arrhythmias
regardless of age), a strategy of coronary angiography with
ntent to perform PCI is a useful approach regardless of the
ime since initiation of fibrinolytic therapy, provided further
nvasive management is not considered futile or unsuitable
iven the clinical circumstances (Table 11). Further discus-
ion of the management of such patients may be found in
ection 5.4.4 (which has been updated in this document) of
he 2005 PCI Guideline Update (13a).
. Rescue PCI
n other patients who do not exhibit the clinical instability
oted above, PCI may also be reasonable if there is clinical
uspicion of failure of fibrinolysis. This is referred to as
escue PCI. Critical to the success of rescue PCI is the
nitial clinical identification of patients who are suspected of
aving failed reperfusion with full-dose fibrinolysis. Because
he presence or absence of ischemic discomfort may be
nreliable for identifying failed reperfusion, clinicians
hould search for evidence of inadequate ST-segment res-
lution on the 12-lead ECG. Operationally, the 12-lead
CG should be scrutinized after adequate time has elapsed
efore making the judgment that fibrinolytic therapy has
ot been effective. Although earlier periods have been used
ary PCI
ines indicate 95% confidence intervals. Reprinted with permission from (74).r Primn some studies, the writing committee felt that 90 minutes
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PCI Focused Update January 15, 2008:172–209able 11. Updates to Section 5.4.4: PCI After Failed Fibrinolysis (All 2005 Recommendations Provided for Clarity)
2005 PCI Guideline Update Recommendation 2007 PCI Focused Update Recommendation Comments
Class I
escue PCI should be performed in patients less than
75 years old with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be
performed within 18 hours of shock unless further
support is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive
care. (Level of Evidence: B)
1. A strategy of coronary angiography with intent to
perform PCI (or emergency CABG) is
recommended for patients who have received
fibrinolytic therapy and have any of the
following:
a. Cardiogenic shock in patients less than 75
years who are suitable candidates for
revascularization. (Level of Evidence: B)
b. Severe congestive heart failure and/or
pulmonary edema (Killip class III). (Level of
Evidence: B)
c. Hemodynamically compromising ventricular
arrhythmias. (Level of Evidence: C)
Modified recommendation (changed LOE
and text)
escue PCI should be performed in patients with severe
congestive heart failure and/or pulmonary edema
(Killip class 3) and onset of symptoms within 12
hours. (Level of Evidence: B)
Deleted recommendation
Class IIa
escue PCI is reasonable for selected patients 75 years
or older with ST elevation or left bundle-branch block
or who develop shock within 36 hours of MI and are
suitable for revascularization that can be performed
within 18 hours of shock. Patients with good prior
functional status who are suitable for
revascularization and agree to invasive care may be
selected for such an invasive strategy. (Level of
Evidence: B)
1. A strategy of coronary angiography with intent to
perform PCI (or emergency CABG) is reasonable
in patients 75 years of age or older who have
received fibrinolytic therapy and are in
cardiogenic shock, provided that they are
suitable candidates for revascularization. (Level
of Evidence: B)
Modified recommendation (changed text)
t is reasonable to perform rescue PCI for patients with
1 or more of the following:
2. It is reasonable to perform rescue PCI for
patients with 1 or more of the following:
2005 recommendation remains current
in 2007 PCI Update
a. Hemodynamic or electrical instability. (Level of
Evidence: C)
a. Hemodynamic or electrical instability. (Level
of Evidence: C)
b. Evidence of persistent ischemia. (Level of Evidence: C) b. Persistent ischemic symptoms. (Level of
Evidence: C)
3. A strategy of coronary angiography with intent to
perform rescue PCI is reasonable for patients in
whom fibrinolytic therapy has failed (ST-segment
elevation less than 50% resolved after 90
minutes following initiation of fibrinolytic therapy
in the lead showing the worst initial elevation)
and a moderate or large area of myocardium at
risk (anterior MI, inferior MI with right ventricular
involvement or precordial ST-segment
depression). (Level of Evidence: B)
New recommendation
Class IIb
escue PCI in the absence of 1 or more of the above
Class I or IIa indications is not recommended. (Level
of Evidence: C)
1. A strategy of coronary angiography with intent to
perform PCI in the absence of 1 or more of the
above Class I or IIa indications might be
reasonable in moderate- and high-risk patients,
but its benefits and risks are not well
established. The benefits of rescue PCI are
greater the earlier it is initiated after the onset
of ischemic discomfort. (Level of Evidence: C)
Modified recommendation (changed COR
from III to IIb and changed text)
Class III
1. A strategy of coronary angiography with intent to
perform PCI (or emergency CABG) is not
recommended in patients who have received
fibrinolytic therapy if further invasive
management is contraindicated or the patient or
designee does not wish further invasive care.
(Level of Evidence: C)
New recommendationABG indicates coronary artery bypass graft; COR, class of recommendation; HF, heart failure; LOE, level of evidence; MI, myocardial infarction; PCI, percutaneous coronary intervention; and STEMI,
T-elevation myocardial infarction.
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January 15, 2008:172–209 PCI Focused Updatefter initiation of fibrinolysis provided the best time for
valuating the need for rescue PCI: hence, if there is less
han 50% ST resolution in the lead showing the greatest
egree of ST-segment elevation at presentation, fibrinolytic
herapy has likely failed to produce reperfusion.
The 2005 PCI Guideline Update (13a) recommendations
or rescue PCI were based on observational data and 2 small
andomized clinical trials (n  179) from the early 1990s
94,95). More recently, MERLIN (Middlesbrough Early
evascularization to Limit Infarction) (n  307) and
EACT (Rescue Angioplasty versus Conservative Treat-
ent or Repeat Thrombolysis) (n  427) and 3 meta-
nalyses have refocused attention on rescue PCI (96–100).
his subject has been studied with fewer than 1000 patients
nrolled in randomized trials.
In the period between trials studying rescue PCI, there
as a transition between angiographic and electrocardio-
raphic diagnosis to detect failed reperfusion. Importantly,
n the earlier studies, rescue PCI was performed in infarct
rteries with TIMI 0/1 flow, often after a protocol-
andated 90-minute angiogram. In MERLIN and RE-
CT, however, patients were randomized if they had less
han 50% ST-segment elevation resolution at 60 or 90
inutes, respectively. Many patients had patent infarct
igure 5. Efficacy End Points for Rescue PCI Versus Conservative
I indicates confidence interval; MERLIN, Middlesbrough Early Revascularization to L
ion; REACT, Rescue Angioplasty versus Conservative Treatment or Repeat Thrombol
anagement of Patients with Early Failure of Thrombolysis for Acute Anterior Myocar
ial Infarction study. Reprinted with permission from (100).rteries at angiography; only 54% of patients in MERLIN mnd 74% of patients in REACT (which required less than
IMI grade 3 flow for PCI) actually underwent PCI. From
procedural standpoint, stents have replaced balloon angio-
lasty, antiplatelet therapy has improved with the addition
f a thienopyridine agent and often a GP IIb/IIIa receptor
ntagonist, and procedural success rates are higher.
Despite these historical differences, recent data support
he initial observation that rescue PCI decreases adverse
linical events compared with medical therapy. In the
ijeysundera meta-analysis (100) (Figure 5), there was a
rend toward reduced mortality rates with rescue PCI from
0.4% to 7.3% (RR 0.69 [95% CI 0.46 to 1.05]; p  0.09),
educed reinfarction rates from 10.7% to 6.1% (RR 0.58
95% CI 0.35 to 0.97]; p  0.04), and reduced HF rates
rom 17.8% to 12.7% (RR 0.73 [95% CI 0.54 to 1.00]; p 
.05). These event rates suggest that high-risk patients were
elected for enrollment, so these data do not define the role
f rescue PCI in lower-risk patients. Also, the benefits of
escue PCI need to be balanced against the risk. There was
n excess occurrence of stroke in 2 trials (10 events versus 2
vents), but the majority were thromboembolic rather than
emorrhagic, and the sample size was small, so more data
re required to define this risk. There was also an increase of
3% in absolute risk of bleeding, suggesting that adjust-
apy
farction trial; NNT, number needed to treat; PCI, percutaneous coronary interven-
ial; RESCUE, Randomized Comparison of Rescue Angioplasty with Conservative
farction trial; RR, relative risk; and TAMI, Thrombolysis and Angioplasty in Myocar-Ther
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PCI Focused Update January 15, 2008:172–209mprove safety. It should be noted that the majority of
atients who underwent rescue PCI received streptokinase
s fibrinolytic therapy.
Given the association between bleeding events and sub-
equent ischemic events (103), it might be reasonable to
elect moderate- and high-risk patients for PCI after
brinolysis and to treat low-risk patients with medical
herapy. As noted above, patients with cardiogenic shock,
evere HF, or hemodynamically compromising ventricular
rrhythmias are excellent candidates. An electrocardio-
raphic estimate of potential infarct size in patients with. PCI After Fibrinolysis or for Patients Not Unde
12) tested the hypothesis that routine PCI for total
o
o
p
(
i
a
cular; Pt 90 minutes after initiation of fibrinolytic therapy in the
ead showing the worst initial elevation) and ongoing
schemic pain is useful in selecting other patients for rescue
CI. Anterior MI or inferior MI with right ventricular
nvolvement or precordial ST-segment depression usually
redicts increased risk (104). Conversely, patients with
ymptom resolution, improving ST-segment elevation (less
han 50% resolution), or inferior MI localized to 3 ECG
eads probably should not be referred for angiography.
ikewise, it is doubtful that PCI of a branch artery
diagonal or obtuse marginal branch) will change prognosis
ersistent ST-segment elevation (less than 50% resolution in the absence of the high-risk criteria noted above.rgoing Primary Reperfusionhe open artery hypothesis suggests that late patency of an
nfarct artery is associated with improved LV function,
ncreased electrical stability, and provision of collateral
essels to other coronary beds for protection against future
vents (see Table 12). The OAT (Occluded Artery Trial)
able 12. Updates to Section 5.4.5: PCI After Successful Fibri
2005 PCI Guideline Update Recommendation 2007 P
C
n patients whose anatomy is suitable, PCI should be performed
when there is objective evidence of recurrent MI. (Level of
Evidence: C)
1. In patie
should
evidenc
n patients whose anatomy is suitable, PCI should be performed
for moderate or severe spontaneous or provocable myocardial
ischemia during recovery from STEMI. (Level of Evidence: B)
2. In patie
be perfo
or provo
recovery
n patients whose anatomy is suitable, PCI should be performed
for cardiogenic shock or hemodynamic instability. (Level of
Evidence: B)
3. In patie
should
hemody
Cl
t is reasonable to perform routine PCI in patients with LV
ejection fraction less than or equal to 0.40, HF, or serious
ventricular arrhythmias. (Level of Evidence: C)
1. It is rea
patients
equal to
arrhyth
t is reasonable to perform PCI when there is documented clinical
heart failure during the acute episode, even though subsequent
evaluation shows preserved LV function (LV ejection fraction
greater than 0.40). (Level of Evidence: C)
2. It is rea
docume
acute e
evaluat
ejection
Evidenc
Cl
CI might be considered as part of an invasive strategy after
fibrinolytic therapy. (Level of Evidence: C)
1. PCI of a
a paten
after ST
invasive
C
1. PCI of a
than 24
in asym
disease
electric
severe
OR/LOE indicates class of recommendation/level of evidence; HF, heart failure; LV, left ventricclusion 3 to 28 days after MI would reduce the composite
f death, reinfarction, or Class IV heart failure. Stable
atients (n 2166) with an occluded infarct artery after MI
about 20% of whom received fibrinolytic therapy for the
ndex event) were randomized to optimal medical therapy
is or for Patients Not Undergoing Primary Reperfusion
used Update Recommendation Comments
ose anatomy is suitable, PCI
formed when there is objective
current MI. (Level of Evidence: C)
2005 recommendation remains current
in 2007 PCI Update
ose anatomy is suitable, PCI should
for moderate or severe spontaneous
myocardial ischemia during
STEMI. (Level of Evidence: B)
2005 recommendation remains current
in 2007 PCI Update
ose anatomy is suitable, PCI
formed for cardiogenic shock or
c instability. (Level of Evidence: B)
2005 recommendation remains current
in 2007 PCI Update
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January 15, 2008:172–209 PCI Focused Updatehe qualifying period of 3 to 28 days was based on calendar
ays; thus, the minimal time from symptom onset to
ngiography was just over 24 hours. Inclusion criteria
ncluded total occlusion of the infarct-related artery with
IMI grade 0 or 1 antegrade flow and LV ejection fraction
LVEF) less than 50% or proximal occlusion of a major
picardial artery with a large risk region. Exclusion criteria
ncluded NYHA Class III or IV heart failure, serum
reatinine greater than 2.5 mg per dL, left main or 3-vessel
isease, clinical instability, or severe inducible ischemia on
tress testing if the infarct zone was not akinetic or dyski-
etic. The 4-year cumulative end point was 17.2% in the
CI group and 15.6% in the medical therapy group (HR
.16 [95% CI 0.92 to 1.45] p  0.2). Reinfarction rates
ended to be higher in the PCI group, which may have
ttenuated any benefit in LV remodeling. There was no
nteraction between treatment effect and any subgroup variable.
Preclinical studies have suggested that late opening of an
ccluded infarct artery may reduce adverse LV remodeling
nd preserve LV volumes. However, 5 previous clinical. Ancillary Therapy for Patients Undergoing PCI
ecommendations may be found in the 2007 STEMI
G
fi
U
a
a
r
c
T-elevamprovement in LVEF or LV end-systolic and end-
iastolic volumes after PCI. The largest of these, the
ECOPI (DEsobstruction COronaire en Post-Infarctus)
rial, found a higher LVEF at 6 months with PCI (105).
OSCA-2 (Total Occlusion Study of Canada) (13) en-
olled 381 stable patients in a mechanistic ancillary study of
AT and had the same eligibility criteria (12). The PCI
rocedure success rate was 92% and the complication rate
as 3%, although 9% had periprocedural MI as measured by
iomarkers. At 1 year, patency rates (n  332) were higher
ith PCI (83% vs. 25%; p less than 0.0001), but each group
n  286) had equivalent improvement in LVEF (4.2% vs.
.5%; p  0.47). There was modest benefit of PCI on
reventing LV dilation over 1 year in a multivariate model,
ut only 42% had paired volume determinations, so it is
nclear whether this finding extends to the whole cohort.
he potential benefit of PCI in attenuating remodeling may
ave been decreased by periprocedural MI and the high rate
f use of beta blockers and ACE inhibitors. There was no
ignificant interaction between treatment effect and time,tudies in 363 patients have demonstrated inconsistent infarct artery, or infarct size.for STEMIhe 2007 STEMI Guidelines Focused Update (106) in-
ludes a new section on the use of anticoagulant therapy for
atients undergoing PCI to establish reperfusion for
TEMI. The recommendations associated with PCI are
ummarized in Table 13.
Full discussion of the background and basis of these
able 13. Ancillary Therapy
2005 PCI Guideline Update
Recommendation 2007 PCI Focuse
C
1. For patients undergoing PCI af
regimen, the following dosing r
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(Level of Evidence: C)
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1. Because of the risk of catheter
used as the sole anticoagulant
anticoagulant with anti-IIa acti
Evidence: C)
Based on 2007 STEMI Focused Update (106).
GP indicates glycoprotein; IV, intravenous; PCI, percutaneous coronary intervention; STEMI, Suidelines Focused Update. When moving to PCI after
brinolytic therapy, those patients who received upstream
FH or enoxaparin can continue to receive those antico-
gulants in a seamless fashion (i.e., without crossover to
nother agent) under the dosing regimens listed in the
ecommendations (106,107). On the basis of reports of
ate Recommendation Comments
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PCI Focused Update January 15, 2008:172–209ary PCI in OASIS-6 (Organization for Assessment of
trategies for Ischemic Syndromes) (7) and the experience
ith fondaparinux in the OASIS-5 trial (108), the STEMI
ocused update writing group recommended that fondapa-
inux should not be used as the sole anticoagulant during
CI but should be coupled with an additional agent that has
nti-IIa activity to ameliorate the risk of catheter compli-
ations. Although bivalirudin or UFH are potential options
or supplemental anticoagulation with fondaparinux, the
vailable experience, albeit limited, is largely with UFH.
he only available data from the CREATE (Clinical Trialial Infarction Treatment Evaluation) trial that bear on this
oint are with UFH (109).
Given the complexities of the characteristics of the
ndividual agents and their actions on the coagulation
ascade, clinicians are cautioned about extrapolating any of
he observations with agents discussed in this update to
ther anticoagulant regimens. In particular, as noted by the
ood and Drug Administration (FDA), the LMWHs are
ufficiently distinct that they should be evaluated individu-
lly rather than considered as a class of interchangeablef Reviparin and Metabolic Modulation in Acute Myocar-
agents (110).
. Antiplatelet Therapy
able 14. Updates to Section 6.2.1: Oral Antiplatelet Therapy
2005 PCI Guideline Update Recommendation
2007 PCI Focused Update
Recommendation Comments
Class I
atients already taking daily chronic aspirin therapy
should take 75 to 325 mg of aspirin before the PCI
procedure is performed. (Level of Evidence: A)
1. Patients already taking daily long-term
aspirin therapy should take 75 mg to
325 mg of aspirin before PCI is
performed. (Level of Evidence: A)
2005 recommendation remains current
in 2007 PCI Update
atients not already taking daily chronic aspirin therapy
should be given 300 to 325 mg of aspirin at least 2
hours and preferably 24 hours before the PCI
procedure is performed. (Level of Evidence: C)
2. Patients not already taking daily long-
term aspirin therapy should be given 300
mg to 325 mg of aspirin at least 2 hours
and preferably 24 hours before PCI is
performed. (Level of Evidence: C)
2005 recommendation remains current
in 2007 PCI Update
fter the PCI procedure, in patients with neither aspirin
resistance, allergy, nor increased risk of bleeding,
aspirin 325 mg daily should be given for at least 1
month after bare-metal stent implantation, 3 months
after sirolimus-eluting stent implantation, and 6
months after paclitaxel-eluting stent implantation,
after which daily chronic aspirin use should be
continued indefinitely at a dose of 75 to 162 mg.
(Level of Evidence: B)
3. After PCI, in patients without allergy or
increased risk of bleeding, aspirin 162 mg
to 325 mg daily should be given for at
least 1 month after BMS implantation, 3
months after sirolimus-eluting stent
implantation, and 6 months after
paclitaxel-eluting stent implantation, after
which daily long-term aspirin use should be
continued indefinitely at a dose of 75 mg
to 162 mg. (Level of Evidence: B)
Modified recommendation (changed
text)
loading dose of clopidogrel should be administered
before PCI is performed. (Level of Evidence: A) An
oral loading dose of 300 mg, administered at least 6
hours before the procedure, has the best established
evidence of efficacy. (Level of Evidence: B)
4. A loading dose of clopidogrel,* generally
600 mg, should be administered before
or when PCI is performed. (Level of
Evidence: C) In patients undergoing PCI
within 12 to 24 hours of receiving
fibrinolytic therapy, a clopidogrel oral
loading dose of 300 mg may be
considered. (Level of Evidence: C)
Modified recommendation (changed
LOE and text)
n patients who have undergone PCI, clopidogrel 75 mg
daily should be given for at least 1 month after bare-
metal stent implantation (unless the patient is at
increased risk of bleeding; then it should be given for
a minimum of 2 weeks), 3 months after sirolimus
stent implantation, and 6 months after paclitaxel
stent implantation, and ideally up to 12 months in
patients who are not at high risk of bleeding. (Level
of Evidence: B)
5. For all post-PCI stented patients receiving
a DES, clopidogrel 75 mg daily should be
given for at least 12 months if patients
are not at high risk of bleeding. For post-
PCI patients receiving a BMS, clopidogrel
should be given for a minimum of 1
month and ideally up to 12 months
(unless the patient is at increased risk of
bleeding; then it should be given for a
minimum of 2 weeks). (Level of
Evidence: B)
Modified recommendation (changed
text)
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January 15, 2008:172–209 PCI Focused Updatehe 2005 PCI Guideline Update (13a) recommended
spirin antiplatelet therapy of 325 mg, which was based
rimarily on results from the TAXUS IV and SIRIUS trials
111–128). Since that time, experience has been gained with
oses of aspirin ranging from 75 mg to 325 mg (see Table
4 for further information and Table 15 for a list of the
rials). No significant trials have been reported comparing
ower-dose aspirin (75 mg to 100 mg) with higher-dose
spirin (162 mg to 325 mg) in subacute or late stent
hrombosis with the incidence of bleeding as the initial
ourse of therapy after placement of drug-eluting stents
DES). Two major trials (129,130) involving patients not
ndergoing placement of DES report an increase in risk of
leeding on higher-dose aspirin. No conclusive data are
vailable regarding higher-dose aspirin and subacute stent
hrombosis among patients who are considered aspirin
esistant.
Continued treatment with the combination of aspirin and
lopidogrel after PCI appears to reduce rates of cardiovas-
ular ischemic events (130,131). On the basis of randomized
linical trial protocols, aspirin 162 mg to 325 mg daily
hould be given for at least 1 month after implantation of a
are-metal stent (BMS), 3 months after implantation of a
irolimus-eluting stent (SES), and 6 months after implan-
ation of a paclitaxel-eluting stent (PES), after which daily
ong-term use of aspirin should be continued indefinitely at
dose of 75 mg to 162 mg. In patients for whom there is
able 14. Continued
2005 PCI Guideline Update Recommendation
200
Cl
f clopidogrel is given at the time of procedure,
supplementation with GP IIb/IIIa receptor
antagonists can be beneficial to facilitate earlier
platelet inhibition than with clopidogrel alone. (Level
of Evidence: B)
1. If clopido
procedure
IIIa recep
beneficia
or patients with an absolute contraindication to
aspirin, it is reasonable to give a 300-mg loading
dose of clopidogrel, administered at least 6 hours
before PCI, and/or GP IIb/IIIa antagonists,
administered at the time of PCI. (Level of Evidence: C)
2. For patie
contraind
reasonab
loading d
at least 6
IIb/IIIa an
time of P
3. In patient
concerne
dose of 7
reasonab
stent imp
Cl
1. Continua
beyond 1
patients u
(Level of
Some uncertainty exists about optimal loading dose of clopidogrel. Randomized trials establish
daily oral dose of 75 mg. Higher oral loading doses such as 600 mg or 900 mg of clopidogre
ggregation, but the additive clinical efficacy and safety of higher oral loading doses have not b
BMS indicates bare-metal stent; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; L
nfarction.oncern about bleeding, the opinion of the writing group is Dhat lower doses of aspirin—75 mg to 162 mg—can be
sed.
Likewise, clopidogrel 75 mg daily should be given for a
inimum of 1 month after implantation of a BMS [mini-
um 2 weeks for patients at significant increased risk of
leeding (132)] and for 12 months after implantation of a
ES or PES and ideally in all patients post PCI who are not
t high risk of bleeding. Under urgent circumstances that
revent the use of clopidogrel for 1 year, the duration
tudied for FDA approvals was 3 months for an SES and 6
onths for a PES. The optimal duration of clopidogrel
herapy after 1 year has not been established and should
epend on the judgment of the risk–benefit ratio for the
ndividual patient. Predictors of late stent thrombosis have
ncluded stenting of small vessels, multiple lesions, long
tents, overlapping stents, ostial or bifurcation lesions, prior
rachytherapy, suboptimal stent result, low ejection frac-
ion, advanced age, diabetes mellitus, renal failure, ACS,
nd premature discontinuation of antiplatelet agents
133,134). Patients should be counseled on the need for and
isks of DAT before placement of intracoronary stents,
specially a DES, and alternative therapies to pursue if they
re unwilling or unable to comply with the recommended
uration of DAT. To reduce the incidence of bleeding
omplications associated with DAT, lower-dose aspirin (75
g to 162 mg daily) is reasonable for long-term therapy
135,136). Given the importance of a 1-year course of
I Focused Update
mmendation Comments
a
given at the time of
lementation with GP IIb/
tagonists can be
el of Evidence: B)
Modified recommendation (changed
text)
h an absolute
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PCI Focused Update January 15, 2008:172–209or 1 year, and among those patients for whom surgery
annot be deferred, aspirin therapy should be considered
uring the perioperative period in high-risk patients with
ES (133).
Several investigations have explored various loading doses
f clopidogrel before or during PCI. Consistent findings are
hat compared with a 300-mg loading dose, doses of either
00 or 900 mg achieve greater degrees of platelet inhibition
ith less variability among patients (137). Fewer patients
ay demonstrate “resistance” or nonresponsiveness to clo-
idogrel following the 600-mg dose. There appears to be no
ignificant additive value of the 900-mg dose over the
00-mg dose (137).
The 600-mg dose appears to achieve maximum inhibition
ore rapidly than the 300-mg dose (138). Superior clinical
utcomes at 30 days, primarily reduction in evidence of MI,
ave been reported after the 600-mg dose given 2 hours
efore the procedure, although this salutary effect was not
onfirmed in 1 investigation (139). No excess hazard has
een reported with the 600-mg compared with the 300-mg
ose for patients treated with fibrinolytic therapy; however,
able 15. Aspirin Dosages of Major Clinical Trials Involving PC
Trial Name Stents Compared
To
Pati
AVEL (111) SES versus BMS 2
-SIRIUS (112) SES versus BMS 3
AXUS I (113) PES versus BMS
AXUS II (114) PES versus BMS 5
AXUS III (115) PES for ISR only
-SIRIUS (116) SES versus BMS 1
ELIVER (117) ACHIEVE versus ML PENTA 10
LUTES (118) PES versus BMS 1
IRIUS (119) SES versus BMS 10
AXUS IV (120) PES versus BMS EXPRESS 13
SAR-DESIRE (121) SES versus PES versus
balloon angioplasty
3
SAR-DIABETES (122) SES versus PES 2
IRTAX (123) SES versus PES 10
AXi (124) SES versus PES 2
AXUS V (125) PES versus BMS 11
AXUS VI (126) PES versus BMS 4
EALITY (127) SES versus PES 13
AXUS V ISR (128) PES versus VBT for ISR 3
CHIEVE indicates a brand-name paclitaxel-coated stent; BMS, bare-metal stent; C-SIRIUS, Can
tent; E-SIRIUS, European Sirolimus-Eluting Stent in Coronary Lesions; h, hour; ISAR-DESIRE, Drug
tent for the Prevention of Restenosis in Diabetic Patients With Coronary Artery Disease; ISR, in-st
oronary intervention; PES, paclitaxel-eluting stent; RAVEL, A Randomized Comparison of a S
andomized Multi-Center Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and
oronary Lesions; SIRTAX, Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for
ardiology; TAXUS V ISR, Paclitaxel-Eluting Stents versus Brachytherapy for In-Stent Restenosisoading doses greater than 300 mg have not been studied b140). Larger trials will more fully evaluate higher doses
f clopidogrel on clinical events, as well as further
valuate safety (e.g., bleeding). The OASIS-7 trial is
omparing 600-mg with 300-mg loading doses of clopi-
ogrel and will provide further evidence about the opti-
al treatment strategy.
There is agreement that the loading dose should be
dministered before PCI. What is unclear is the precise time
hen the loading dose must be given to achieve a desirable
herapeutic effect. Evidence from the CREDO (Clopi-
ogrel for the Reduction of Events During Observation)
rial suggests that with a 300-mg dose, 6 hours is the
inimum time (131). With the 600-mg dose, 2 hours may
e sufficient (141), although maximal platelet inhibition
ay not be achieved until 3 to 4 hours (142).
Long-term clopidogrel therapy alone may not achieve
dequate inhibition for PCI. Patients on long-term therapy
ith clopidogrel experience significant additional incremen-
al inhibition of platelet aggregation when given a loading
ose (143). In patients treated with fibrinolytic therapy,
owever, loading doses of greater than 300 mg have not
Duration of Treatment Aspirin Dose
Indefinite 100 mg once a day
Indefinite 100 mg once a day
Greater than or equal to 12
months
Greater than 80 mg
once a day
Indefinite 75 mg once a day
Not stated Greater than or equal
to 75 mg
Indefinite 81 to 325 mg once a
day
1 year 325 mg once a day
3 months Not stated
Indefinite 325 mg once a day
Indefinite 325 mg once a day
Indefinite 500 mg IV during; 100
mg bid after
Indefinite 100 mg twice a day
Indefinite 100 mg once a day
“Long term” 100 mg once a day
Indefinite 325 mg once a day
Greater than or equal to 6
months
75 mg at least 2 hours
prior; greater than
or equal to 75 mg
after
Indefinite 100 mg once a day
Indefinite (9-month minimum,
indefinite recommended)
325 mg once a day
irolimus-Eluting Stent in Coronary Lesions; ELUTES, European evaLUation of pacliTaxel Eluting
Stents for in-stent REstenosis; ISAR-DIABETES, Paclitaxel-Eluting Stent Versus Sirolimus-Eluting
tenosis; IV, intravenous; ML PENTA, multilink stainless steel bare metal stent; PCI, percutaneous
s-Eluting Stent With a Standard Stent for Coronary Revascularization; REALITY, Prospective
clitaxel-Eluting Stent (TAXUS); SES, sirolimus-eluting stent; SIRIUS, Sirolimus-Eluting Stent in
ry Revascularization; TAXi, Paclitaxel and sirolimus stents in the real world of interventional
BT, vascular brachytherapy.I
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I, percu.1. Selection of a Bare-Metal or Drug-Eluting Stent
bservational studies indicate that physicians routinely
mplant stents when performing coronary interventions.
wo types of stents are available: BMS and DES. Drug-
luting stents have become increasingly popular as standard
herapy. In 2005, a sampling of 140 US hospitals indicated
hat 94% of patients treated with a stent received at least 1
ES (145). More recently, however, because of concerns
bout stent thrombosis and the mandate that each DES-
reated patient take prolonged DAT, the proportion of
ES use has declined to 60% to 70%.
The results of the clinical trials that led to FDA approval
f the DES provide support for its use in suitable patients.
xtended follow-up of the initial investigated patient co-
orts to 4 years confirms the sustained benefit of DES in
ecreasing the need for repeat revascularization but without
ifferences in death or MI (146–148). Randomized clinical
rials in selected clinical subsets such as BMS in-stent
estenosis, total occlusions, diabetes mellitus, and small-
iameter arteries have also demonstrated the value of DES
nd have prompted physicians to extend the application of
able 16. Updates to Section 7.3.5: Drug-Eluting and Bare-Me
2005 PCI Guideline Update Recommendation 2007 PCI
C
drug-eluting stent (DES) should be considered
as an alternative to the bare-metal stent in
subsets of patients in whom trial data
suggest efficacy. (Level of Evidence: A)
1. A DES shou
BMS in tho
indicate a
(Level of E
2. Before imp
cardiologis
need for an
patient’s a
therapy for
3. In patients
PCI and ar
procedures
during the
be given to
of balloon
implantatio
(Level of E
Cl
1. In patients
about risk
162 mg of
Evidence: C
Cl
DES may be considered for use in anatomic
settings in which the usefulness,
effectiveness, and safety have not been fully
documented in published trials. (Level of
Evidence: C)
1. A DES may
anatomic s
effectivene
has not be
(Level of E
MS indicates bare-metal stent; DAT, dual antiplatelet therapy; DES, drug-eluting stent; and PCES beyond the narrow patient populations included in the Mnitial approval trials (122,126,149–154). The duration of
ollow-up of these “off-label” studies and the small number
f patients enrolled, however, limit the detection of subtle
ifferences in important end points such as stent thrombo-
is, death, or MI.
It is important to recognize certain differences between
he BMS and DES when selecting a stent for an individual
atient or lesion. First, in general, a DES may be more
ifficult to implant than a BMS. The DES has a polymer
oating that stiffens the stent and makes it less conformable.
ccordingly, one reason for using a BMS is that it can be
sed in patients in whom a DES cannot be implanted
uccessfully. Second, the DES is substantially more expen-
ive than the BMS. When financial resources are limited,
se of the DES may be rationed, with implantation only in
hose patients at greatest risk for restenosis.
A third but very important difference relates to the
nhibition of endothelial coverage of the DES and the need
or extended DAT (Table 16). After introduction of the
MS, it was associated with a disturbingly high incidence of
tent thrombosis (141). Stent thrombosis often presented as
tents
sed Update Recommendation Comments
considered as an alternative to a
tients for whom clinical trials
ble effectiveness/safety profile.
e: A)
Modified recommendation
(changed text)
g a DES, the interventional
ld discuss with the patient the
ation of DAT and confirm the
o comply with the recommended
(Level of Evidence: B)
New recommendation
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y to require invasive or surgical
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PCI Focused Update January 15, 2008:172–209fter implantation. Changes in technique such as high
nflation pressure and intravascular ultrasound (IVUS)-
uided deployment and use of concomitant combined aspi-
in and thienopyridine therapy substantially reduced the
ncidence of stent thrombosis to a clinically acceptable level
155). Importantly, the requisite duration of DAT was only
weeks, and some advocated only 2 weeks. The importance
f DAT in preventing stent thrombosis was further
trengthened by the outcome of patients for whom DAT
as discontinued prematurely because of the need for those
atients to undergo surgical procedures. These patients
xperienced a disturbingly high incidence of stent throm-
osis (156). The critical role of DAT in preventing stent
hrombosis was also noted among patients with BMS who
ad received brachytherapy for in-stent restenosis. Presum-
bly these patients were less likely to develop subsequent
eointimal coverage of the endoluminal stent surface and
ere accordingly then more susceptible to stent thrombosis.
In the initial randomized trials that compared the DES
ith BMS, DAT was administered for 30 days to 6 months.
he most recent guidelines update describes a minimum
uration of 3 months of DAT for an SES and 6 months for
PES. On the basis of results from other trials that suggest
sustained benefit of DAT, these guidelines further state
hat ideally DAT should be extended to 12 months.
lthough these recommendations were to some extent
rbitrary, subsequent studies have confirmed that premature
iscontinuation of DAT, that is, at a time less than
minimal duration” (3 months for the SES and 6 months for
he PES) was highly associated with stent thrombosis (157).
The tight relationship between DAT and stent throm-
osis for patients treated with DES warrants emphasis and
as implications for selecting the type of stent deployed at
he time of PCI. For example, the clinician should not select
DES for a patient who does not have access to DAT for
nancial reasons or who is unlikely to be compliant in taking
AT. One study revealed that 14% of patients had stopped
AT 1 month after implantation of the DES (158). Also,
mplantation of a BMS may be more appropriate in a
atient with a known increased risk of bleeding. In situa-
ions such as these, the consequences of developing reste-
osis are considered less untoward than those of stent
hrombosis or significant bleeding.
Furthermore, prescribed premature discontinuation of
AT in patients treated with a DES should not be done
asually. For example, routine dental procedures should not
ustify cessation of DAT even though it is anticipated DAT
ill be subsequently resumed (133). Consideration should
e given to delay scheduling of elective procedures that
ormally warrant discontinuation of antiplatelet agents. The
enefit of DES in reducing the need for target vessel
evascularization (TVR) also should be taken into account.
ome registries have shown 1-digit TVR rates with the
MS, and the absolute reduction in these events using the
ES depends on patient and lesion characteristics. pThere are also concerns related to the appropriate dura-
ion of DAT. More recently, the occurrence of late (up to 1
ear) or very late (beyond 1 year) stent thrombosis among
ES-treated patients has been described (159). One data-
ase analysis suggests that extended use of DAT may have
alue in preventing late stent thrombosis, whereas others
isagree (160).
Outcomes of patients in the initial FDA-approval trials
o 4 years provides reassurance that, at least for those types
f patients, despite a small excess of stent thrombosis, there
ppears to be no increase in death or MI when comparing
ES-treated groups with BMS-treated groups. As noted,
rotocol-recommended DAT in these patients was not
ore than 6 months, although extended DAT was not
rohibited. (These results are observed despite a significant
xcess occurrence of stent thrombosis among patients who
eceived a paclitaxel stent.) Some have postulated that the
ubstantial additional revascularization procedures experi-
nced by BMS patients were associated with a small but
ignificant excess rate of death and MI that offset any deaths
r MIs that may have occurred in the DES group related to
tent thrombosis.
Less data are available regarding the outcomes of patients
ho receive a DES for an “off-label” indication. Such
atients have characteristics of their coronary disease, for
xample, a lesion in an artery less than 2.5 mm in diameter,
ery long lesions, bifurcation lesions, or a clinical syndrome
uch as acute MI, that were excluded in the FDA-approval
rials. Reports from large observational studies indicate that
off-label” patients may experience higher rates of repeat
evascularization and death and MI at 1 year than DES
atients with “on-label” features. Importantly, a similar
elationship is observed for patients treated with a BMS. In
ddition, there appears to be a significant association be-
ween “off-label” use and stent thrombosis. Accordingly, the
ppropriate selection for DAT among “off-label” DES
atients may be different than for “on-label” patients.
At this point in time, 12 months of DAT is recom-
ended for all patients who receive a DES (120) (see
ection 6.2.1) unless there is a high risk of bleeding. The
enefits and indications for treatment with DAT beyond 1
ear in patients with DES are the subject of ongoing studies.
ow-dose aspirin should be continued indefinitely. For
atients with clinical features associated with stent throm-
osis, such as renal insufficiency, diabetes, or procedural
haracteristics such as multiple stents or treatment of a
ifurcation lesion, extended DAT beyond 1 year may be
easonable. The risk of stent thrombosis needs to be
alanced with other medical conditions and nonmedical
actors that might affect the risk-benefit ratio of DAT
ersus other therapies. Finally, certain DES-treated patients
ave already discontinued DAT 1 year after stent implan-
ation. No information yet supports restarting DAT in these
atients.
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able 17 presents revised recommendations based on the
006 AHA/ACC Secondary Prevention Guidelines for
atients with Coronary and Other Atherosclerotic Vas-
ular Diseases (11). This table replaces Table 26 from the
005 PCI Guideline Update (13a). Classes of recommen-
ation and a corresponding level of evidence have been
dded for all recommendations. There is a new recom- lendation for annual influenza vaccination, and the
ection on antiplatelet agents/anticoagulants has been
odified slightly to reflect the recent evidence on aspirin
osage in patients who have undergone PCI with stent
lacement. Other changes since publication of the 2006
CC/AHA Secondary Prevention Guidelines include
he addition of recommended daily physical activity and
Class IIa recommendation for lowered low-densityipoprotein cholesterol.able 17. Comprehensive Risk Reduction for Patients With Coronary and Other Vascular Disease After PCI
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
Smoking
Goal: Complete cessation, no exposure to environmental tobacco smoke
sk about tobacco status at every visit. 1. Status of tobacco use should be asked about at
every visit.
I (B) Modified recommendation
(changed text)
trongly encourage patient and family
to stop smoking and avoid
secondhand smoke.
2. Every tobacco user and family members who
smoke should be advised to quit at every visit.
I (B) No content change
ssess the tobacco user’s willingness
to quit.
3. The tobacco user’s willingness to quit should be
assessed.
I (B) No content change
ssist by counseling and developing a
plan for quitting.
4. The tobacco user should be assisted by counseling
and developing a plan for quitting.
I (B) No content change
rrange follow-up, referral to special
programs, or pharmacological
therapy (including nicotine
replacement and bupropion).
5. Follow-up, referral to special programs, or
pharmacotherapy (including nicotine replacement
and pharmacological treatment) should be
arranged.
I (B) No content change
rge avoidance of exposure to
environmental tobacco smoke at
work and home.
6. Exposure to environmental tobacco smoke at work
and home should be avoided.
I (B) No content change
Blood Pressure Control
Goal: Less than 140/90 mm Hg or less than 130/80 mm Hg if patient has diabetes or chronic kidney disease
nitiate or maintain lifestyle
modification (weight control,
increased physical activity, alcohol
moderation, moderate sodium
restriction, and emphasis on fruits,
vegetables, and low-fat dairy
products) in all patients.
1. For patients with blood pressure greater than or
equal to 140/90 mm Hg (or greater than or equal
to 130/80 mm Hg for patients with diabetes or
chronic kidney disease), it is recommended to
initiate or maintain lifestyle modification—weight
control; increased physical activity; alcohol
moderation; sodium reduction; and emphasis on
increased consumption of fresh fruits, vegetables,
and low-fat dairy products.
I (B) No content change
dd blood pressure medication,*
emphasizing the use of beta
blockers and inhibitors of the renin-
angiotensin-aldosterone system.
2. For patients with blood pressure greater than or
equal to 140/90 mm Hg (or greater than or equal
to 130/80 mm Hg for patients with diabetes or
chronic kidney disease), it is useful as tolerated, to
add blood pressure medication, treating initially
with beta blockers and/or ACE inhibitors, with the
addition of other drugs such as thiazides as
needed to achieve goal blood pressure.
I (A) Modified recommendation
(changed text)
Lipid Management
Goal: LDL-C substantially less than 100 mg per dL
(If triglycerides are greater than or equal to 200 mg per dL, non–HDL-C should be less than 130 mg per dL†.)
tart dietary therapy in all patients
(less than 7% of total calories as
saturated fat and less than
200 mg/d cholesterol).
1. Starting dietary therapy is recommended. Reduce
intake of saturated fats (to less than 7% of total
calories), trans fatty acids, and cholesterol (to less
than 200 mg per day).
I (B) Modified recommendation
(changed text)
TP
E
A
L
I
I
I
A
198 King III et al. JACC Vol. 51, No. 2, 2008
PCI Focused Update January 15, 2008:172–209able 17. Continued
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
2. Adding plant stanol/sterols (2 g per day) and/or
viscous fiber (greater than 10 g per day) is
reasonable to further lower LDL-C.
IIa (A) New recommendation
romote physical activity and weight
management.
3. Promotion of daily physical activity and weight
management is recommended.
I (B) Modified recommendation
(changed text)
ncourage increased consumption of
omega-3 fatty acids in fish‡ or 1 g/d
omega-3 fatty acids from
supplements for risk reduction (for
treatment of elevated triglycerides,
higher doses are usually necessary
for risk reduction).
4. It may be reasonable to encourage increased
consumption of omega-3 fatty acids in the form of
fish‡ or in capsules (1 g per day) for risk reduction.
For treatment of elevated triglycerides, higher
doses are usually necessary for risk reduction.
IIb (B) No content change
ssess fasting lipid profile in all
patients, preferably within 24 hours
of an acute event. For hospitalized
patients, initiate lipid-lowering
medication as recommended below
before discharge according to the
following guide:
5. A fasting lipid profile should be assessed in all
patients and within 24 hours of hospitalization for
those with an acute cardiovascular or coronary
event. For hospitalized patients, initiation of lipid-
lowering medication is indicated as recommended
below before discharge according to the following
schedule:
I (A) Modified recommendation
(changed text)
DL-C less than 100 mg/dL (baseline
or on treatment): Statins preferred to
lower LDL-C.
● LDL-C should be less than 100 mg per dL. I (A) Modified recommendation
(changed text)
● Further reduction of LDL-C to less than 70 mg per
dL is reasonable.
IIa (A) New recommendation
f LDL-C is greater than or equal to 100
mg/dL (baseline or on treatment),
initiate or intensify LDL-C–lowering
therapy with drug treatment. May
require combination therapy with
standard-dose ezetimide, bile acid
sequestrant, or niacin.
● If baseline LDL-C is greater than or equal to 100
mg per dL, LDL-lowering drug therapy§ should be
initiated.
I (A) Modified recommendation
(changed text)
● If on-treatment LDL-C is greater than or equal to
100 mg per dL, intensify LDL-lowering drug
therapy (may require LDL-lowering drug
combination¶) is recommended.
I (A) New recommendation
● If baseline LDL-C is 70 to 100 mg per dL, it is
reasonable to treat to LDL-C less than 70 mg per
dL.
IIa (B) New recommendation
f triglycerides are greater than or
equal to 150 mg/dL or HDL-C is less
than 40 mg/dL, emphasize weight
management and physical activity.
Advise smoking cessation.
● If triglycerides are greater than or equal to 150
mg per dL or HDL-C is less than 40 mg per dL,
weight management, physical activity, and
smoking cessation should be emphasized.
I (B) Modified recommendation
(changed text)
f triglycerides are 200 to 499 mg/dL: ● If triglycerides are 200 to 499 mg per dL††, non–
HDL-C target should be less than 130 mg per dL.
I (B) Modified recommendation
(changed text)
● If triglycerides are 200 to 499 mg per dL††,
further reduction of non–HDL-C to less than 100
mg per dL is reasonable.
IIa (B) New recommendation
6. Therapeutic options to reduce non–HDL-C include:
● More intense LDL-C–lowering therapy is indicated. I (B) New recommendation
fter LDL-C–lowering therapy,**††
consider adding fibrate or niacin¶
● Niacin (after LDL-C–lowering therapy) can be
beneficial.
IIa (B) Modified recommendation
(changed text)
● Fibrate therapy‡‡ (after LDL-C–lowering therapy)
can be beneficial.
IIa (B) Modified recommendation
(changed text)
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f triglycerides are greater than or
equal to 500 mg/dL:
Consider fibrate or niacin§ before
LDL-C–lowering therapy.¶††
Consider omega-3 fatty acids as an
adjunct for high triglycerides.
7. If triglycerides are greater than or equal to 500 mg
per dL,††§§ therapeutic options indicated and
useful to prevent pancreatitis are fibrate§‡‡ or
niacin§ before LDL-lowering therapy, and treat
LDL-C to goal after triglyceride-lowering therapy.
Achieving a non–HDL-C of less than 130 mg per dL
is recommended.
I (C) Modified recommendation
(changed text)
Physical Activity
Goal: 30 minutes 5 days per week; optimal daily
ardiac rehabilitation programs are
recommended, particularly for
patients with multiple modifiable
risk factors and/or moderate- to
high-risk patients for whom
supervised exercise training is
warranted.
1. Advising medically supervised programs (cardiac
rehabilitation) for high-risk patients (e.g., recent
acute coronary syndrome or revascularization,
heart failure) is recommended.
I (B) Modified recommendation
(changed text)
ssess risk, preferably with exercise
testing, to guide prescription.
2. For all patients, it is recommended that risk be
assessed with a physical activity history and/or an
exercise test to guide prescription.
I (B) Modified recommendation
(changed text)
ncourage a minimum of 30 to 60
minutes of activity, preferably daily
or at least 5 days per week (brisk
walking, jogging, cycling, or other
aerobic activity) supplemented by an
increase in daily lifestyle activities
(e.g., walking breaks at work,
gardening, and household work).
3. For all patients, encouraging 30 to 60 minutes of
moderate-intensity aerobic activity is
recommended, such as brisk walking on most—
preferably all—days of the week, supplemented by
an increase in daily lifestyle activities (e.g., walking
breaks at work, gardening, and household work).
I (B) Modified recommendation
(changed text)
ncourage resistance training 2 days
per week.
4. Encouraging resistance training 2 days per week
may be reasonable.
IIb (C) No content change
Weight Management
Goal: BMI: 18.5 to 24.9 kg/m2
Waist circumference: men less than 40 inches (102 cm), women less than 35 inches (89 cm)
alculate BMI and measure waist
circumference as part of evaluation.
Monitor response of BMI and waist
circumference to therapy.
1. It is useful to assess BMI and/or waist
circumference on each visit and consistently
encourage weight maintenance/reduction through
an appropriate balance of physical activity, caloric
intake, and formal behavioral programs when
indicated to maintain/achieve a BMI between 18.5
and 24.9 kg/m2.
I (B) Modified recommendation
(changed text)
tart weight management and physical
activity as appropriate. Desirable
BMI range is 18.5 to 24.9 kg/m2.
2. The initial goal of weight-loss therapy should be to
reduce body weight by approximately 10% from
baseline. With success, further weight loss can be
attempted if indicated through further assessment.
I (B) Modified recommendation
(changed text)
f waist circumference is 35 inches or
greater in women or 40 inches or
greater in men, initiate lifestyle
changes and treatment strategies
for metabolic syndrome.
3. If waist circumference (measured horizontally at
the iliac crest) is 35 inches (89 cm) or greater in
women and 40 inches (102 cm) or greater in men,
it is useful to initiate lifestyle changes and consider
treatment strategies for metabolic syndrome as
indicated.
I (B) Modified recommendation
(changed text)
Diabetes Management
Goal: HbA1c less than 7%
ppropriate glucose-lowering therapy
to achieve near-normal fasting
plasma glucose, as indicated by
HbA1c.
1. It is recommended to initiate lifestyle and
pharmacotherapy to achieve near-normal HbA1c.
I (B) Modified recommendation
(changed text)
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reatment of other risk factors (e.g.,
physical activity, weight
management, blood pressure, and
cholesterol management).
2. Beginning vigorous modification of other risk
factors (e.g., physical activity, weight management,
blood pressure control, and cholesterol
management as recommended above) is
beneficial.
I (B) Modified recommendation
(changed text)
3. Coordination of diabetic care with the patient’s
primary care physician or endocrinologist is
beneficial.
I (C) New recommendation
Antiplatelet Agents/Anticoagulants: Aspirin
or all post-PCI stented patients,
aspirin 325 mg daily should be given
for at least 1 month after BMS
implantation, 3 months after
sirolimus stent implantation, and 6
months after paclitaxel stent
implantation, after which daily long-
term aspirin  (75 mg to 162 mg
per day) should be continued
indefinitely in all patients if not
contraindicated.
1. For all post-PCI stented patients without allergy or
increased risk of bleeding, aspirin 162 mg to 325
mg daily should be given for at least 1 month after
BMS implantation, 3 months after sirolimus-eluting
stent implantation, and 6 months after paclitaxel-
eluting stent implantation, after which long-term
aspirin use should be continued indefinitely at a
dose of 75 mg to 162 mg daily.
I (B) Modified recommendation
(changed text)
2. In patients for whom the physician is concerned
about risk of bleeding, lower-dose 75 mg to 162
mg of aspirin is reasonable during the initial
period after stent implantation.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Clopidogrel
or post-PCI stented patients,
clopidogrel 75 mg per day should be
given for at least 1 month after BMS
implantation, 3 months after
sirolimus stent implantation, and 6
months after paclitaxel stent
implantation, after which clopidogrel
should ideally be continued for up to
12 months in all stented patients
who are not at high risk of bleeding.
1. For all post-PCI patients who receive a DES,
clopidogrel 75 mg daily should be given for at
least 12 months if patients are not at high risk
of bleeding. For post-PCI patients receiving a
BMS, clopidogrel should be given for a minimum
of 1 month and ideally up to 12 months (unless
the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks).
I (B) Modified recommendation
(changed text)
2. For all post-PCI non-stented STEMI patients,
treatment with clopidogrel should continue for
at least 14 days.
I (B) New recommendation
3. Long-term maintenance therapy (e.g., 1 year)
with clopidogrel (75 mg per day orally) is
reasonable in STEMI and non-STEMI patients
who undergo PCI without reperfusion therapy.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Warfarin
anage warfarin to an INR of 2.5 to
3.5 for post-MI patients when
clinically indicated or for those not
able to take aspirin or clopidogrel.
1. Managing warfarin to an INR equal to 2.0 to 3.0
for paroxysmal or chronic atrial fibrillation or flutter
is recommended, and in post-MI patients when
clinically indicated (e.g., atrial fibrillation, left
ventricular thrombus).
I (A) Modified recommendation
(changed text)
2. Use of warfarin in conjunction with aspirin and/or
clopidogrel is associated with an increased risk of
bleeding and should be monitored closely.
I (B) New Recommendation
3. In patients requiring warfarin, clopidogrel, and
aspirin therapy after PCI, an INR of 2.0 to 2.5 is
recommended with low dose aspirin (75 mg to
81 mg) and a 75-mg dose of clopidogrel.
I (C) New recommendation
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Renin-Angiotensin-Aldosterone System Blockers: ACE Inhibitors
onsider use of ACE inhibitors for all
CHD patients indefinitely; start early
after MI in stable high-risk patients
(anterior MI, previous MI, Killip class
greater than or equal to II [S3 gallop,
rales, radiographic HF]).
1. ACE inhibitors should be started and continued
indefinitely in all patients with LVEF less than or
equal to 40% and for those with hypertension,
diabetes, or chronic kidney disease, unless
contraindicated.
I (A) Modified recommendation
(changed text)
se as needed to manage blood
pressure or consider for long-term
therapy in all other patients.
2. ACE inhibitors should be started and continued
indefinitely in patients who are not lower risk
(lower risk defined as those with normal LVEF in
whom cardiovascular risk factors are well
controlled and revascularization has been
performed), unless contraindicated.
I (B) Modified recommendation
(changed text)
ontinue indefinitely for all patients
with LV dysfunction (ejection fraction
less than or equal to 0.40) or
symptoms of heart failure.
3. Among lower risk patients (i.e., those with normal
LVEF in whom cardiovascular risk factors are well
controlled and revascularization has been performed)
use of ACE inhibitors is reasonable.
IIa (B) Modified recommendation
(changed text)
Renin-Angiotensin-Aldosterone System Blockers: Angiotensin Receptor Blockers
se angiotensin receptor blockers in
post-STEMI patients who are intolerant
of ACE inhibitors and who have either
clinical or radiological signs of heart
failure or LVEF less than 0.40.
1. Use of angiotensin receptor blockers is
recommended in patients who are intolerant of
ACE inhibitors and have HF or have had an MI with
LVEF less than or equal to 40%.
I (A) Modified recommendation
(changed text)
2. Angiotensin receptor blockers are useful in
other patients who are ACE-inhibitor intolerant
and have hypertension.
I (B) New recommendation
3. Considering use in combination with ACE inhibitors
in systolic dysfunction HF may be reasonable.
IIb (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade
ldosterone blockade in post-STEMI
patients without significant renal
dysfunction¶¶ or hyperkalemia***
who are already receiving
therapeutic doses of an ACE
inhibitor, have an LVEF less than or
equal to 0.40, and have either
diabetes or heart failure.
1. Use of aldosterone blockade in post-MI patients
without significant renal dysfunction¶¶ or
hyperkalemia*** is recommended in patients who
are already receiving therapeutic doses of an ACE
inhibitor and beta blocker, have an LVEF of less
than or equal to 40%, and have either diabetes or
HF.
I (A) Modified recommendation
(changed text)
Beta Blockers
tart in all post-MI and acute patients
(arrhythmia, LV dysfunction,
inducible ischemia). Continue for a
minimum of 6 months; continue
indefinitely in patients with STEMI.
Observe usual contraindications.
1. It is beneficial to start and continue beta-blocker
therapy indefinitely in all patients who have had
MI, acute coronary syndrome, or LV dysfunction
with or without HF symptoms, unless
contraindicated.
I (A) Modified recommendation
(changed text)
se as needed to manage angina,
rhythm, or blood pressure in all other
patients.
2. It is reasonable to consider long-term therapy for
all other patients with coronary or other vascular
disease or diabetes unless contraindicated.
IIa (C) Modified recommendation
(changed text)
Influenza Vaccination
1. Patients with cardiovascular disease should have
an annual influenza vaccination.
I (B) New recommendation
ecommendations in bold type are those the writing committee felt deserved extra emphasis. The 2007 PCI recommendations are written in complete sentences, in accordance with ACC/AHA Guidelines
ethodology. “No content change” indicates the updated recommendation now includes a LOE and COR and a verb consistent with that LOE and COR as outlined in the ACC/AHA LOE/COR table (Table
). *For compelling indications for individual drug classes in specific vascular diseases, see the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment
f High Blood Pressure (JNC 7) (161). †Non-HDL-C indicates total cholesterol minus HDL-C. ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. §When
DL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C less than 70 mg per dL is the chosen target, consider drug titration to achieve this level to minimize
ide effects and cost. When LDL-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of greater than 50% in LDL-C levels
y either statins or LDL-C–lowering drug combinations. Dietary supplement niacin must not be used as a substitute for prescription niacin. ¶Standard dose of statin with ezetimibe, bile acid sequestrant,
r niacin. **Treat to a goal of non–HDL-C substantially less than 130 mg/dL. ††The use of resin is relatively contraindicated when triglycerides are greater than 200 mg per dL. ‡‡The combination
f high-dose statin plus fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. §§Patients with very high triglycerides should not consume alcohol.
he use of bile acid sequestrant is relatively contraindicated when triglycerides are greater than 200 mg/dL. Some recommend avoiding regular use of ibuprofen, which may limit the cardioprotective
ffects of aspirin. Use of cyclo-oxygenase-2 inhibitors may be associated with an increased incidence of cardiovascular events. ¶¶Creatinine should be less than 2.5 mg per dL in men and less than
.0 mg per dL in women. ***Potassium should be less than 5.0 mEq per L.
ACE indicates angiotensin-converting enzyme; BMI, body mass index; COR, class of recommendation; CHF, congestive heart failure; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; INR,nternational normalized ratio; LDL-C, low-density lipoprotein cholesterol; LOE, level of evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention;
nd STEMI, ST-elevation myocardial infarction.
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